

10000000000000

A P P L I C A T I O N

for

UNITED STATES LETTERS PATENT

on

NOVEL DEATH DOMAIN PROTEINS

by

John C. Reed

Adam Godzik

Krzysztof Pawlowski

Loredana Fiorentino

Sug Hyung Lee

Wilfried Roth

and

Frank Stenner-Liewen

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"EXPRESS MAIL" MAILING LABEL NUMBER: EL 857 041 358 US

Sheets of Drawings: 32

DATE OF DEPOSIT: November 15, 2001

Docket No.: P-LJ 5037

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE  
"EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER  
37 C.F.R. 1.10 ON THE DATE INDICATED ABOVE, AND IS  
ADDRESSED TO: COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231.

Karly Tambra

(TYPED OR PRINTED NAME OR PERSON MAILING PAPER OR FEE)



(SIGNATURE OF PERSON MAILING PAPER OR FEE)

Attorneys

CAMPBELL & FLORES LLP

4370 La Jolla Village Drive, Suite 700  
San Diego, California 92122

USPTO CUSTOMER NO. 23601

**NOVEL DEATH DOMAIN PROTEINS**

This invention was made with government support under grant numbers AG15393 and CA68390 awarded by the National Institutes of Health. The United States Government  
5 has certain rights in this invention.

This application claims the benefit of U.S. Provisional Application No. 60/\_\_\_\_\_, filed November 17, 2000, which was converted from U.S. Serial No. 09/715,893, and of U.S. Provisional Application No.  
10 60/301,889, filed June 29, 2001, both of which are incorporated herein by reference.

] Ordud  
GJ  
9/10/03

**BACKGROUND OF THE INVENTION**

This invention relates generally to the fields of molecular biology and molecular medicine and more specifically to proteins involved in the regulation of immunological response and cell death.  
15

Programmed cell death is a physiologic process that ensures homeostasis is maintained between cell production and cell turnover in essentially all self-renewing tissues. In many cases, characteristic  
20 morphological changes, termed "apoptosis," occur in a dying cell. Since similar changes occur in different types of dying cells, cell death appears to proceed through a common pathway in different cell types.

25 In addition to maintaining tissue homeostasis, apoptosis also occurs in response to a variety of external stimuli, including growth factor deprivation, alterations in

calcium levels, free-radicals, cytotoxic lymphokines, infection by some viruses and bacteria, radiation and most chemotherapeutic agents. Thus, apoptosis is an inducible event that likely is subject to similar mechanisms of regulation as occur, for example, in a metabolic pathway. In this regard, dysregulation of apoptosis also can occur and is observed, for example, in some types of cancer cells, which survive for a longer time than corresponding normal cells, and in neurodegenerative diseases where neurons die prematurely. In viral and certain bacterial infections, induction of apoptosis can figure prominently in the pathophysiology of the disease process, because immune-based eradication of viral or bacterial infections depend on elimination of virus or bacteria-producing host cells by immune cell attack resulting in apoptosis.

It has long been recognized that viruses harbor genes that regulate apoptosis of host cells, making vital contributions to the virus life-cycle. Some types of bacteria, such as *Chlamydiae* species, have also been found to regulate apoptosis in host cells. Previous studies have established that infection of mammalian cells with *Chlamydiae* species can either suppress or induce apoptosis, depending on whether examined early or late in the infection cycle of these obligate intracellular bacteria. However, the bacterial genes responsible for the regulation of host cell apoptosis are not known.

Tumor Necrosis Factor (TNF) family cytokines play an important role in a wide variety of immunological, allergic, and inflammatory responses. Several members of the TNF family have been identified, including TNF $\alpha$ ,

Lymphotoxin- $\alpha$ , Lymphotoxin- $\beta$ , LIGHT, CD27 Ligand (CD27L), CD30L, CD40L, Fas-L, Trail, and others. These molecules are generally produced as Type-II integral membrane proteins on the surface of cells, undergoing subsequent release into the extracellular milieu as a result of proteolytic cleavage. Many of the TNF-family cytokines however remain anchored in the plasma membrane, relying on interactions with receptor-bearing cells through cell-cell contact. The receptors for TNF-family cytokines are equally diverse. All members of the family have a conserved arrangement of cysteines in their extracellular domains, which is one of the criteria for membership in this family.

The intracellular cytosolic domain of TNF-family receptors are diverse in their amino acid sequences, but can be broadly classified into two types: (a) those that contain a protein-interaction module known as a Death-Domain (TNFR1, Fas, DR3, DR4, DR5, DR6, p75NTR) and those that do not (TNFR2, CD27, CD30, CD40, LT $\beta$ R, 4B1 and others). Death Domains are responsible for interactions of a subgroup of the TNF-Receptor (TNFR) family with adapter proteins which bind in turn to caspase-family intracellular proteases involved in inducing apoptosis (programmed cell death). However, the Death Domains can also mediate binding to other types of adaptor molecules which bind kinases or other types of signaling molecules rather than proteases. For example, several death domain proteins participate in regulation of NF $\kappa$ B induction during an inflammatory response.

Although some of the proteins involved in programmed cell death have been identified and associations among some of these proteins have been described, additional

apoptosis regulating proteins remain to be found.

Furthermore, the mechanisms by which these proteins mediate their activity remains to be elucidated. The identification of the proteins involved in cell death and an understanding

5 of the associations between these proteins can provide a means for manipulating the process of apoptosis in a cell and, therefore, selectively regulating the relative lifespan of a cell or its relative resistance to cell death stimuli.

The identification of new proteins or new domains  
10 within known proteins, and the elucidation of the proteins with which they interact, can form the basis for strategies designed to alter apoptosis, cytokine production, cytokine receptor signaling, and other cellular processes. Such new proteins can thus be used to develop therapeutic  
15 applications for controlling apoptosis.

Thus, a need exists to identify novel apoptosis-related domains within both novel and known proteins. The present invention satisfies this need and provides additional advantages as well.

20

#### SUMMARY OF THE INVENTION

In accordance with the present invention, there are provided novel death domain (DD) and death effector domain (DED) polypeptides. The invention also provides nucleic acid molecules encoding DDs and DEDs, vectors  
25 containing these nucleic acid molecules and host cells containing the vectors. The invention also provides antibodies that can specifically bind to invention DDs and DEDs. Such DDs and DEDs and/or anti-DD or DED antibodies

are useful for discovery of drugs that suppress infection, autoimmunity, inflammation, allergy, allograft rejection, sepsis, and other diseases, and can be used in the treatment of inflammatory diseases.

5           The present invention provides a death domain-containing protein, CTDD, from *Chlamydia trachomatis* that can induce apoptosis. In addition, corresponding death domains from other *Chlamydia* species are provided. The invention also provides nucleic acid molecules encoding 10 these polypeptides, vectors containing these nucleic acid molecules, host cells containing the vectors, and antibodies that can specifically bind to these polypeptides.

The present invention also provides a screening assay useful for identifying agents that can effectively alter the association of an invention DD or DED with itself 15 or with other proteins. By altering the self-association of DDs or DEDs or by altering their interactions with other proteins, an effective agent can increase or decrease the activation of kinases, or modulate cellular pathways that effect apoptosis, cell proliferation, cell adhesion, cell 20 stress responses, responses to microbial infection, B cell immunoglobulin class switching, and the like.

The invention also provides methods of altering the activity of a DD or DED in a cell, wherein such 25 increased or decreased activity of a DD or DED can modulate the level of kinase activity or cellular pathways that effect apoptosis, cell proliferation, cell adhesion, cell stress responses, responses to microbial infection, B cell immunoglobulin class switching, and the like. For example,

the activity of DD or DED in a cell can be increased by introducing into the cell and expressing a nucleic acid sequence encoding this polypeptide or proteins comprising such DD or DED. In addition, the activity of DD or DED, or

5 DD/DED-comprising proteins in a cell can be decreased by introducing into the cell and expressing an antisense nucleotide sequence that is complementary to a portion of a nucleic acid molecule encoding the DD/DED or DD/DED-comprising proteins.

10 The invention also provides methods for using an agent that can specifically bind DD or DED or a nucleotide sequence that can bind to a nucleic acid molecule encoding DD or DED to diagnose a pathology that is characterized by an altered level of apoptosis, cell proliferation, cell  
15 adhesion, cell stress responses, responses to microbial infection, and B cell immunoglobulin class switching due to an increased or decreased level of DD or DED in a cell.

#### BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows that DAP3, a DED-containing  
20 protein, associates with FADD and regulates FADD-induced apoptosis. binding activity, association with FADD, and regulation of FADD-induced apoptosis was tested (Figure 1). Figure 1A shows association of endogenous DAP3 with endogenous FADD by immunoprecipitation. Figure 1B shows  
25 Fas-inducible association of DAP3 with FADD in transfected HEK293T cells. Figure 1C DAP3 binding to the DED of FADD in transfected 293T cells. Figure 1D shows mapping of FADD-binding region in DAP3 using transfected 293T cells. Figure 1E shows that DAP3 modulates Fas-mediated generation of

caspase-8-like protease activity in transfected 293T cells. Lysates were assayed for caspase-8 protease activity. Figure 1F shows regulation of Fas- and FADD-induced apoptosis by DAP3 in transfected 293-EBNA cells.

5           Figure 2 shows DAP3 binding to the prodomain of pro-Caspase8 and regulation of caspase-8 activation. Figure 2A shows immunoblots of co-immunoprecipitates of transfected 293T cells. Figure 2B shows association of the proximal region of DAP3 with pro-Caspase8 in co-immunoprecipitates of 10 transfected 293T cells. Figure 2C shows that DAP3 binds GTP and stimulates activation of pro-Caspase8 *in vitro* in a GTP-dependent manner.

15           Figure 3 shows that DAP3 directly binds the cytosolic domain of DR4 and modulates Trail Receptor-induced apoptosis. Figure 3A shows that the Death domain of DR4 is required for association with DAP3 in transfected 293T cells. Figure 3B shows that purified recombinant DAP3 binds purified DR4 cytosolic domain. Figure 3C shows mapping of a region in DAP3 required for binding DR4. Figure 3D shows 20 that DAP3 mediates binding of DR4 and DR5 to FADD in a yeast 3-hybrid assay. Figure 3E shows that DAP3 association with FADD and pro-Caspase8 is GTP-dependent. Figure 3F shows that DAP3 modulates apoptosis induction by Trail Receptors in transfected 293-EBNA cells. Figure 3G shows that 25 endogenous DAP3 is required for TRAIL-induced apoptosis using antisense oligonucleotides.

          Figure 4 shows sequence analysis of DAP3. Figure 4A shows a schematic representation of human DAP3 protein, indicating locations of NB-ARC-like and DED-like domain, as

well as position of the P-loop motif. Figure 4B shows an alignment of the amino acid sequence of NB-ARC domains of human Apaf-1 (SEQ ID NO:29) and *C. elegans* CED4 (SEQ ID NO:30) with residues 115-213 of DAP3 (SEQ ID NO:4).

- 5 Asterisks indicate nucleotide-binding motifs. Figure 4C shows a sequence alignment of DEDs of pro-Caspase 8 (SEQ ID NOS:31 and 32 for DED1 and DED2, respectively), pro-caspase 10 (SEQ ID NOS:33 and 34 for DED1 and DED2, respectively), and FADD (SEQ ID NO:35) with residues 268-337 of DAP3 (SEQ  
10 ID NO:2). Identical and similar residues are indicated in black and gray blocks, respectively.

Figure 5 shows a model of the IRAK signal transduction pathway for the Toll/interleukin-1 (IL-1) receptor family.

- 15 Figure 6 shows the expression pattern of IRAK4 mRNA.

Figure 7 shows the association of IRAK4 with members of the hToll/IL-1 receptor transduction pathway.

- 20 Figure 8 shows regulation of NF $\kappa$ B activity by IRAK4.

Figure 9 shows an alignment of the DED domain of DED4 (SEQ ID NO:8) with other DED-containing proteins (hDEDD, SEQ ID NO:36; mDEDD, SEQ ID NO:37; fDEDD, SEQ ID NO:38; FADD, SEQ ID NO:39).

Figure 10 shows the nucleotide (SEQ ID NO:15) and amino acid (SEQ ID NO:16) sequence of a newly identified variant of IRAK4.

Figure 11 shows the DD for *Chlamydia muridarum* 5 (SEQ ID NO:53); DD for *Chlamydia pneumoniae* (SEQ ID NO:56); DD for *Chlamydophila psittaci* (SEQ ID NO:58); nucleotide (SEQ ID NO:54) and amino acid (SEQ ID NO:55) sequence of *Chlamydia muridarum*, and amino acid sequence of *Chlamydia pneumoniae* (SEQ ID NO:57).

10 Figure 12 shows that CTDD and DR-5 can be co-immunoprecipitated *in vitro*.

Figure 13 shows the induction of apoptosis by CTDD.

15 Figure 14 shows the induction of caspase activity by CTDD.

Figure 15 shows the correlation between apoptosis and CTDD gene expression at various times post-infection with *Chlamydia*.

#### DETAILED DESCRIPTION OF THE INVENTION

20 In accordance with the present invention, there are provided novel Death Domains (DDs), Death Effector Domains (DEDs) and NB-ARC domains of newly identified DD and DED proteins, and fragments thereof, as well as novel DD- and DED-containing polypeptides. As used herein, an 25 invention DD can refer to a peptide region that shares

sequence homology with the DD domain of DD proteins such as TNFR1, Fas, DR3, DR4/TrailR1, DR5/TrailR2, DR6, FADD, MyD88, Raidd, IRAK, IRAK-2, IRAK-M, p75NTR, Tradd, DAP kinase, RIP, NMP84, and ankyrins, and have been found herein to have  
5 binding properties similar to those of other known DD  
proteins. As used herein, an invention DED can refer to a  
peptide region that shares sequence homology with the DED  
domain of DED proteins such as FADD, caspases such as  
caspases 8 and 10, Flip, PEA15, Flash, BAP31, BAR,  
10 DEDT/DEDD, and DAP3, and have been found herein to have  
binding properties similar to those of other known DED  
proteins.

Apoptosis-inducing members of the Tumor Necrosis Factor (TNF) receptor family recruit the proforms of  
15 caspase-family cell death proteases to liganded receptor complexes through interactions of their intracellular Death Domains (DDs) with adapter proteins (Ashkenazi and Dixit, Science 281:1305-1308 (1998); Wallach et al., Annu. Rev. Immunol. 17:331-367 (1999)). Several caspase family members  
20 are known, for example, caspase-1, caspase-2, caspase-3, caspase-4, caspase-5, caspase-6, caspase-7, caspase-8, caspase-9, caspase-10, caspase-11, caspase-12, caspase-13, and caspase-14 (Grutter, Curr. Opin. Struct. Biol. 10:649-655 (2000)). The present invention provides newly  
25 identified proteins containing DDs or DEDs. The death domain is a conserved protein interaction domain, which usually participates in signal transduction pathways governed by members of the TNF family of cytokine receptors, Toll-family receptors, and/or regulation of apoptosis.

Death receptors such as TNF-R1 and Fas oligomerize to signal via their intracellular DDs. The signal is transported by cytosolic adapters to caspases. The Death Inducing Signaling Complex (DISC) for Fas has been shown to 5 encompass minimally a Fas trimer, Fadd, and Caspase-8. A similar DISC complex has been found for DR4 and DR5. In the case of the TRAIL receptors, mixed complexes, for example, two DR4s plus one DR5 to form a trimer, appear to be functional. Decoy receptors, for example, DcR1, DcR2 and 10 DcR3, which have no or incomplete death domains, can inhibit apoptosis possibly by interfering with DISC formation. Other types of DED-containing proteins such as mammalian Flip and viral Flip proteins can compete for binding to DISC components, suppressing caspase activation. Caspase 15 activation in the DISC occurs by the "induced proximity" mechanism (Salvesen, Structure Fold Des. 7:R225-229 (1999)), the first example of caspase activation by this mechanism.

*Caenorhabditis elegans* cell death gene ced-4 encodes a protein that contains a CARD domain and a 20 ATP-binding oligomerization domain called an NB-ARC domain (van der Biezen and Jones, Curr. Biol. 8:R226-R227). The CARD domain of the CED-4 protein interacts with the CARD domain of a pro-caspase called CED-3. The NB-ARC domain allows CED-4 to self-associate, thereby forming an 25 oligomeric complex which brings associated pro-CED-3 molecules into close proximity to each other. Because most pro-caspases possess at least a small amount of protease activity even in their unprocessed form, the assembly of a complex that brings the proforms of caspase into 30 juxtaposition can result in trans-processing of zymogens, producing the proteolytically processed and active caspase.

Thus, CED-4 employs a CARD domain for binding a pro-caspase and an NB-ARC domain for self-oligomerization, resulting in caspase clustering, proteolytic processing and activation.

The nucleotide-binding protein DAP3 (Kissil et al., J. Biol. Chem. 270:27932-27936 (1995); Kissil et al., EMBO J. 18:353-362 (1999)) was identified as a component of death receptor complexes, during a two-hybrid screen for FADD-binding proteins (Kissil et al., J. Biol. Chem. 270:27932-27936 (1995)). As disclosed herein, DAP3 associates with the adapter protein FADD through a domain resembling Death Effector Domains (DEDs) and also binds directly to the DDs of the Trail Receptors DR4 and DR5 via its nucleotide-binding domain, which was determined to bind GTP but not ATP. DAP3 also binds and induces activation of pro-Caspase-8 *in vitro* in a GTP-dependent manner. Moreover, DAP3 is required in intact cells for efficient caspase activation and apoptosis induction by death receptors based on antisense ablation and experiments with trans-dominant inhibitory DAP3 mutants, including mutation of the nucleotide-binding site in DAP3. Thus, DAP3 represents a functionally important component of the caspase-activating, death-inducing signaling complex (DISC) of TNF-family death receptors, and serves as a molecular bridge that recruits FADD to the TRAIL receptors, DR4 and DR5. The presence of a nucleotide-binding site in DAP3 suggests novel opportunities for pharmacological suppression of death receptor signaling, which could have broad therapeutic applications.

The intracellular regions of several TNFR-family members (TNFR1; p75NTR, neurotrophin receptor, also called p75NGFR, nerve growth factor receptor; Fas; DR3;

DR4/TrailR1; DR5/TrailR2; DR6) contain a structure known as the "Death Domain" (DD) and induce apoptosis when bound by ligand (Ashkenazi and Dixit, Science 281:1305-1308 (1998); Wallach et al., Annu. Rev. Immunol. 17:331-367 (1999)). The mechanism of apoptosis induction by such "death receptors" involves recruitment to the receptor complex of adapter proteins, which bind the prodomains of certain caspase-family cell death proteases. Caspases are present in living cells as zymogens, typically requiring proteolytic processing for their activation. Because the proforms of caspases possess weak protease activity, however, their receptor-mediated clustering results in trans-proteolysis through the "induced proximity" mechanism (Salvesen et al., Proc. Natl. Acad. Sci. USA 96:10964-10967 (1999)). It remains unclear what constellation of proteins is required for achieving the correct stoichiometry of receptor complex components, thereby properly positioning the active sites of pro-caspases relative to each other for efficient proteolytic activation of clustered caspase zymogens. Moreover, adapter proteins which recruit caspases to some TNF-family death receptors, such as the Trail receptors DR4 and DR5, are currently unknown (Schneider et al., Immunity 7:831-836 (1997); Walczak et al., EMBO J. 16:5386-5397 (1997); Kischkel et al., Immunity 12:611-620 (2000); Sprick et al., Immunity 12:599-609 (2000).

The functions of the DD, DED and NB-ARC domain containing proteins, generally, supports the role of invention DDs, DEDs and NB-ARC domains and invention DD, DED and NB-ARC domain proteins in cellular pathways that effect apoptosis, cell proliferation, cell adhesion, cell stress

responses, responses to microbial infection, and B cell immunoglobulin class switching.

For example, invention DDs, DEDs and NB-ARC domains have been found to associate with other proteins, 5 including proteins comprising DD and DED domains. Exemplary DD and DED proteins to which invention DDs, DEDs and NB-ARC domains bind include FADD, caspases such as caspase-8, DR4, DR5, MyD88 and Fas. An invention DD protein IRAK4 was also found to bind to Traf6 and hToll. As used herein, the term 10 "bind" or "binding" refers to the association of an invention DD, DED or NB-ARC polypeptide with another protein relatively specifically and, therefore, can form a bound complex. In particular, the binding of a DD, DED or NB-ARC domain to a protein is sufficiently specific such that the 15 bound complex can form *in vivo* in a cell or *in vitro* under suitable conditions.

In one embodiment, it has been found that the invention DAP3 DED (SEQ ID NO:2) binds the DED of FADD. An N-terminal domain of DAP3 containing an NB-ARC domain (SEQ 20 ID NO:4) was also found to bind to caspase-8 and to stimulate pro-caspase-8 protease activity. Additionally, an N-terminal domain of DAP3 containing an NB-ARC domain (SEQ ID NO:4) was found to bind the DD of DR4, and DAP3 was found to bind to DR5 as well. DAP3 was also found to bind GTP, 25 and GTP binding was found to be critical for DAP3 interactions with FADD and caspase-8 but not for TRAIL receptors such as DR4 and DR5. Furthermore, it was found that DAP3 deletion mutants at the N-terminus and C-terminus (DAP3 $\Delta$ N and DAP3 $\Delta$ C, respectively) inhibited FADD-induced 30 activation of pro-caspase-8. Therefore, DAP3 domains,

including DED domain, can function as inhibitors of FADD-induced activation of pro-caspase-8.

In another embodiment, it has been found that IRAK4 can bind to TRAF6, hToll and MyD88. IRAK4 was also 5 found to stimulate NF $\kappa$ B activation. Overexpression of a dominant-negative form of TRAF6 inhibited the IRAK4-mediated NF $\kappa$ B activation. The IRAK4 DD functions as a dominant negative of MyD88-induced NF $\kappa$ B activation and can bind the DD of MyD88. The invention provides an IRAK4 DD (SEQ ID 10 NO:6).

In still another embodiment, a *Chlamydia trachomatis* DD protein (CTDD) (SEQ ID NO:10) was found to bind to various DD containing proteins, including FasR, DR4 and DR5. The invention also provides a DD from *Chlamydia muridarum* (SEQ ID NO:53), *Chlamydia pneumoniae* (SEQ ID 15 NO:56), and *Chlamydophila psittaci* (SEQ ID NO:58). In yet another embodiment, a new DED-containing protein, designated DED4, was identified. Thus, the invention provides a DED4 DED (SEQ ID NO:8).

20 In another embodiment, a mouse DD-containing protein, NIDD, was found to interact with itself and with p75NTR, also known as neurotrophin receptor or nerve growth factor (NGF) receptor. Thus, the invention provides a NIDD DD (SEQ ID NO:12).

25 It has also been found that invention DDs, DEDs and NB-ARC domains modulate a variety of cellular pathways. Proteins that bind to the invention DDs, DEDS, and NB-ARC domains, generally, are well known in the art as modulating

the cellular pathways that effect apoptosis, cell proliferation, cell adhesion, cell stress responses, responses to microbial infection, and B cell immunoglobulin class switching, and NF- $\kappa$ B and JNK are further known to 5 modulate these pathways. Thus, those of skill in the art will recognize that it is within the scope of the invention that DDs, DEDs and NB-ARCs, as well as other newly identified domains, modulate one or more cellular pathways that effect apoptosis, cell proliferation, cell adhesion, 10 cell stress responses, responses to microbial infection, and B cell immunoglobulin class switching.

Presently preferred DDs, DEDs and NB-ARC domain of the invention include amino acid sequences that comprise the same or substantially the same protein sequence set forth in 15 SEQ ID NOS:2, 4, 6, 8, 10, 12, 53, 56 and 58, as well as biologically active, modified forms thereof. The invention also provides DD, DED and NB-ARC domain polypeptides having the same or substantially the same sequence as SEQ ID NOS:18 or 22.

20 In another embodiment, invention DDs, DEDs and NB-ARC domains include proteins comprising fragments having the sequence SEQ ID NOS:2, 4, 6, 8, 10, 12, 53, 56 or 58, or polypeptides having the sequence SEQ ID NOS:16, 18, 20, 22 or 26, which retain at least one native biological DD, DED 25 or NB-ARC activity, such as immunogenicity, the ability to bind to FADD, caspases such as caspase-8, DR4, DR5, TRAF6, hToll, MyD88, and Fas, or other polypeptides, as disclosed herein, the ability to modulate apoptosis, cell proliferation, cell adhesion, cell stress responses,

responses to microbial infection, or B cell immunoglobulin class switching.

Use of the terms "isolated" and/or "purified" in the present specification and claims as a modifier of DNA,  
5 RNA, polypeptides or proteins means that the DNA, RNA, polypeptides or proteins so designated have been produced in such form by the hand of man, and thus are separated from their native *in vivo* cellular environment, and are substantially free of any other species of nucleic acid or  
10 protein. As a result of this human intervention, the recombinant DNAs, RNAs, polypeptides and proteins of the invention are useful in ways described herein that the DNAs, RNAs, polypeptides or proteins as they naturally occur are not.

15 As used herein, "eukaryotic" refers to the variety of species from which an invention DD, DED or NB-ARC is derived, e.g., yeast, slime mold, plant, insect, nematode, mammal, and the like. A preferred DD, DED or NB-ARC domain polypeptide herein is mammalian DAP3, IRAK4, DED4 and NIDD.  
20 The invention also provides a DD protein from *Chlamydia* and, therefore, an invention DD can be from bacteria. As used herein, "mammalian" refers to the variety of species from which a preferred invention DD, DED or NB-ARC is derived, e.g., human, rat, mouse, rabbit, monkey, baboon, bovine,  
25 porcine, ovine, canine, feline, and the like.

The term "biologically active" or "functional", when used herein as a modifier of invention DDS, DEDs or NB-ARC domain, or polypeptide fragment thereof, refers to a polypeptide that exhibits functional characteristics similar

to an invention DD, DED or NB-ARC domain. For example, one biological activity of a DD, DED or NB-ARC domain is the ability to bind, preferably *in vivo*, to a molecule in apoptotic pathways such as FADD, caspases such as caspase-8, DR4, DR5, TRAF6, hToll, MyD88, and Fas proteins. Such DD, DED or NB-ARC binding activity can be assayed, for example, using the methods described in the Examples described herein.

Another biological activity of DD, DED or NB-ARC is the ability to act as an immunogen for the production of polyclonal and monoclonal antibodies that bind specifically to an invention DD, DED or NB-ARC domain. Thus, an invention DD, DED or NB-ARC will encode a polypeptide specifically recognized by an antibody that also specifically recognizes the DDs, DEDs or NB-ARC domains having the amino acid sequence SEQ ID NOS:2, 4, 6, 8, 10, 12, 53, 56 or 58. Such immunologic activity can be assayed by any method known to those of skill in the art. For example, a test DD, DED or NB-ARC polypeptide can be used to produce antibodies, which are then assayed for their ability to bind to an invention DD, DED or NB-ARC comprising SEQ ID NOS:2, 4, 6, 8, 10, 12, 53, 56 or 58. If the antibody binds to the test polypeptide and a protein including the sequence SEQ ID NOS:2, 4, 6, 8, 10, 12, 53, 56 or 58, with the same or substantially the same affinity, then the polypeptide possesses the requisite immunologic biological activity. Similarly, a biological activity of an invention DD or DED polypeptide, including those having SEQ ID NOS:16, 18, 20, 22 or 26, and more preferably SEQ ID NOS:18 or 22, can also have an immunologic biological activity.

DOCUMENT NUMBER

The DED-containing protein DAP3 set forth in SEQ ID NO:14 was initially identified as and implicated in death receptor-mediated apoptosis through unknown mechanisms (Kissil et al., EMBO J. 18:353-362 (1999)). A NB-ARC domain 5 was also identified in DAP3. The subject application represents the first identification of a portion of this protein as forming a DED and NB-ARC domain.

The DD-containing protein IRAK4 set forth in SEQ ID NO:16 was initially identified as a putative protein 10 kinase (Scanlan et al., Int. J. Cancer 83:456-464 (1999); GenBank GI|5360131, putative protein kinase NY-REN-64 antigen). The subject application represents the first identification of a portion of this protein as forming a DD domain. In addition, the IRAK4 protein set forth in SEQ ID 15 NO:16 contains four amino acid changes compared to the GenBank sequence.

The DD-containing protein CTDD set forth in SEQ ID NO:20 was found in the genome of *Chlamydia trachomatis*. The subject application represents the first identification of a 20 portion of this protein as forming a DD domain. In addition, the CTDD protein set forth in SEQ ID NO:20 contains one amino acid change compared to the GenBank sequence of CT-610 from *Chlamydia trachomatis*. The invention further provides other DD-containing proteins and domains of 25 other *Chlamydia* species, including *Chlamydia muridarum*, as disclosed herein.

The DED-containing protein DED4 set forth in SEQ ID NO:18 was identified as a relative of DEDD. DED4 was predicted from nucleotide sequences (chromosomal DNA and EST

DNA) GI Nos. 4210498, 1832773, and 6990020. The subject application represents the first identification of a protein comprising the DED4 sequence or a portion of this protein as forming a DED domain.

5

The DD-containing protein NIDD (NGF receptor-interacting death domain) set forth in SEQ ID NO:22 was identified and found to bind to itself or NGF receptor. The NIDD protein was predicted from mouse nucleotide sequences (EST database at NCBI, GI 5353348), and rat and bovine homologues (GI 4607778 and GI 6960635, respectively) were also found. The subject application represents the first identification of a protein comprising the NIDD sequence or a portion of this protein as forming a DD domain.

15

In accordance with one embodiment of the invention, it has been found that the invention DAP3 DED (SEQ ID NO:2) binds the DED of FADD. An N-terminal domain of DAP3 containing a NB-ARC domain (SEQ ID NO:4) was also found to bind to caspase-8 and to stimulate pro-caspase-8 protease activity. Additionally, an N-terminal domain of DAP3 containing a NB-ARC domain (SEQ ID NO:4) was found to bind the DD of DR4, and DAP3 was found to bind to DR5 as well. DAP3 was also found to bind GTP, and GTP binding was found to be critical for DAP3 interactions with FADD and caspase-8 but not for TRAIL receptors such as DR4 and DR5. Furthermore, it was found that DAP3 deletion mutants at the N-terminus and C-terminus (DAP3 $\Delta$ N and DAP3 $\Delta$ C, respectively) inhibited FADD-induced activation of pro-caspase-8. Therefore, DAP3 domains, including DED domain, can function as inhibitors of FADD-induced activation of pro-caspase-8.

30

P00004745

In another embodiment, the invention provides an IRAK4 DD (SEQ ID NO:6) and that IRAK4 can bind to TRAF6, hToll and MyD88. IRAK4 was also found to stimulate NF<sub>K</sub>B activation. Overexpression of a dominant negative form of 5 TRAF6 inhibited the IRAK4-mediated NF<sub>K</sub>B activation. The IRAK4 DD functions as a dominant negative of MyD88-induced NF<sub>K</sub>B activation.

In still another embodiment, a *Chlamydia trachomatis* DD protein (CTDD) (SEQ ID NO:10) was found to 10 bind to various DD-containing proteins, including FasR, DR4 and DR5. In yet another embodiment, a new DED-containing protein, designated DED4, was identified. Thus, the invention provides a DED4 DED (SEQ ID NO:8). The invention also provides a new protein, NIDD, containing a DD (SEQ ID 15 NO:12), that binds to NGF receptor.

Those of skill in the art will recognize that numerous residues of the above-described sequences can be substituted with other, chemically, sterically and/or electronically similar residues without substantially 20 altering the biological activity of the resulting receptor species. In addition, larger polypeptide sequences containing the same or substantially the same sequence as amino acids set forth in SEQ ID NOS:2, 4, 6, 8, 10, 12, 53, 56 and 58, therein (e.g., splice variants) are contemplated, 25 provided that the sequence is not SEQ ID NOS:14, 24, 28, 55 or 57.

As employed herein, the term "substantially the same amino acid sequence" refers to amino acid sequences having at least about 70% identity with respect to the

reference amino acid sequence, and retaining comparable functional and biological activity characteristic of the protein defined by the reference amino acid sequence. Preferably, proteins having "substantially the same amino acid sequence" will have at least about 80%, more preferably 90% amino acid identity with respect to the reference amino acid sequence; with greater than about 95% amino acid sequence identity being especially preferred. It is recognized, however, that polypeptides (or nucleic acids referred to hereinbefore) containing less than the described levels of sequence identity arising as splice variants or that are modified by conservative amino acid substitutions, or by substitution of degenerate codons are also encompassed within the scope of the present invention. Identity of any two amino acid sequences can be determined by those skilled in the art based, for example, on a BLAST 2.0 computer alignment, using default parameters (Altschul et al., J. Mol. Biol. 215:403-410 (1990); Gish and States, Nature Genet. 3:266-272 (1993); Madden et al., Meth. Enzymol. 266:131-141 (1996); Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997); Zhang and Madden, Genome Res. 7:649-656 (1997)).

The invention DDs, DEDs and NB-ARC domains can be isolated by a variety of methods well-known in the art, e.g., recombinant expression systems described herein, precipitation, gel filtration, ion-exchange, reverse-phase and affinity chromatography, and the like. Other well-known methods are described in Deutscher et al., Guide to Protein Purification: Methods in Enzymology Vol. 182, (Academic Press, (1990)), which is incorporated herein by reference. Alternatively, the isolated polypeptides of the present

invention can be obtained using well-known recombinant methods as described, for example, in Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Plainview NY (1989)).

5 An example of the means for preparing the invention DD(s), DED(s) or NB-ARC domain(s) is to express nucleic acids encoding the DD, DED or NB-ARC domain in a suitable host cell, such as a bacterial cell, a yeast cell, an amphibian cell (i.e., oocyte), or a mammalian cell, using  
10 methods well known in the art, and recovering the expressed polypeptide, again using well-known methods. Invention polypeptides can be isolated directly from cells that have been transformed with expression vectors as described below herein. The invention polypeptide, biologically functional  
15 fragments, and functional equivalents thereof can also be produced by chemical synthesis. For example, synthetic polypeptides can be produced using Applied Biosystems, Inc. Model 430A or 431A automatic peptide synthesizer (Foster City, CA) employing the chemistry provided by the  
20 manufacturer.

Also encompassed by the term DD, DED or NB-ARC domains are functional fragments or polypeptide analogs thereof. The term "functional fragment" refers to a peptide fragment that is a portion of a full length DD, DED, or NB-  
25 ARC domain provided that the portion has a biological activity, as defined above, that is characteristic of the corresponding full length protein. For example, a functional fragment of an invention DD, DED or NB-ARC domain can have an activity such as the ability, for example, to  
30 bind FADD, caspases such as caspase-8, DR4, DR5, TRAF6,

hToll, MyD88, Fas, or p75NTR proteins, or to modulate NF- $\kappa$ B activity or JNK activity, or to modulate the level of cell proliferation, apoptosis, cell adhesion, cell stress responses, responses to microbial infection, class switching, and the like. In addition, the characteristic of a functional fragment of invention DDs, DEDs or NB-ARC domains to elicit an immune response is useful for obtaining an anti-DD, anti-DED or anti-NB-ARC antibodies. Thus, the invention also provides functional fragments of invention DDs, DEDs, or NB-ARCs which can be identified using the binding and routine methods, such as bioassays described herein.

The term "polypeptide analog" includes any polypeptide having an amino acid residue sequence substantially the same as a sequence specifically shown herein in which one or more residues have been conservatively substituted with a functionally similar residue and which displays the ability to functionally mimic a DD, DED or NB-ARC domain as described herein. Examples of conservative substitutions include the substitution of one non-polar (hydrophobic) residue such as isoleucine, valine, leucine or methionine for another, the substitution of one polar (hydrophilic) residue for another such as between arginine and lysine, between glutamine and asparagine, between glycine and serine, the substitution of one basic residue such as lysine, arginine or histidine for another, or the substitution of one acidic residue, such as aspartic acid or glutamic acid for another.

The amino acid length of a peptide, functional fragment, or polypeptide analog of the present invention can range from about 5 amino acids up to one residue less than a full-length protein sequence of an invention DD, DED or NB-ARC. In certain embodiments, the amino acid lengths include, for example, at least about 10 amino acids, at least about 20, at least about 30, at least about 40, at least about 50, at least about 75, at least about 100, at least about 150, at least about 200, at least 213, at least about 250, at least about 300, at least about 350 or more amino acids in length up to one residue less than a full-length DD-, DED, or NB-ARC domain-containing protein sequence.

Preferably, a fragment comprises a sequence selected from SEQ ID NOS:2, 4, 6, 8, 10, 12, 53, 56 or 58. Such a fragment can also include, in addition to invention DDs, DEDs, or NB-ARC domains, at least about 10 residues at its amino-terminus, carboxy-terminus, or both; at least about 20 residues at its amino-terminus, carboxy-terminus, or both; at least about 30 residues at its amino-terminus, carboxy-terminus, or both; at least about 40 residues at its amino-terminus, carboxy-terminus, or both; at least about 50 residues at its amino-terminus, carboxy-terminus, or both; at least about 60 residues at its amino-terminus, carboxy-terminus, or both; at least about 100 residues at its amino-terminus, carboxy-terminus, or both. A fragment can also include, in addition to invention DDs, DEDs, or NB-ARC domains, less than about 10 residues at its amino-terminus, carboxy-terminus, or both; less than about 20 residues at its amino-terminus, carboxy-terminus, or both; less than about 30 residues at its amino-terminus, carboxy-terminus,

or both; less than about 40 residues at its amino-terminus, carboxy-terminus, or both; less than about 50 residues at its amino-terminus, carboxy-terminus, or both; less than about 60 residues at its amino-terminus, carboxy-terminus,  
5 or both; less than about 100 residues at its amino-terminus, carboxy-terminus, or both.

More preferably, a fragment comprises a sequence selected from SEQ ID NOS:2, 4, 6, 8, 10, 12, 53, 56 or 58, further comprising one or more domains selected from DAP3,  
10 IRAK4, CTDD, DED4 or NIDD. Most preferably, a fragment has at least one fewer domains than the domains in proteins from SEQ ID NOS:14, 16, 18, 20, or 22, wherein the domains are selected from those present in DAP3, IRAK4, CTDD, DED4 or NIDD, either domains previously identified or domains newly  
15 identified as disclosed herein. Identification of the domains in proteins from SEQ ID NOS:14, 16, 18, 20 or 22 can be carried out by reference to publications reporting such proteins (e.g., Kissil et al., EMBO J. 18:353-362 (1999) for DAP3). A fragment can also comprise a sequence selected  
20 from SEQ ID NOS:2, 4, 6, 8, 10, 12, 53, 56 or 58 having at least one fewer amino acids than in SEQ ID NOS:14, 16, 18, 20 or 22.

As used herein the phrase "conservative substitution" also includes the use of a chemically  
25 derivatized residue in place of a non-derivatized residue, provided that such polypeptide displays the required binding activity. The phrase "chemical derivative" refers to a subject polypeptide having one or more residues chemically derivatized by reaction of a functional side group. Such  
30 derivatized molecules include, for example, those molecules

in which free amino groups have been derivatized to form  
amine hydrochlorides, p-toluene sulfonyl groups,  
carbobenzoxy groups, t-butyloxycarbonyl groups, chloroacetyl  
groups or formyl groups. Free carboxyl groups may be  
5 derivatized to form salts, methyl and ethyl esters or other  
types of esters or hydrazides. Free hydroxyl groups may be  
derivatized to form O-acyl or O-alkyl derivatives. The  
imidazole nitrogen of histidine may be derivatized to form  
N-im-benzylhistidine. Also included as chemical derivatives  
10 are those peptides which contain one or more naturally  
occurring amino acid derivatives of the twenty standard  
amino acids. For example: 4-hydroxyproline may be  
substituted for proline; 5-hydroxylysine may be substituted  
for lysine; 3-methylhistidine may be substituted for  
15 histidine; homoserine may be substituted for serine; and  
ornithine may be substituted for lysine. Polypeptides of  
the present invention also include any polypeptide having  
one or more additions and/or deletions of residues, relative  
to the sequence of a polypeptide whose sequence is shown  
20 herein, so long as the required activity is maintained.

In accordance with another embodiment, novel DD-,  
DED-, or NB-ARC-containing proteins are provided. Invention  
DD-, DED-, or NB-ARC-containing proteins refer to a protein  
comprising an invention DD, DED, or NB-ARC including SEQ ID  
25 NOS:2, 4, 6, 8, 10, 12, 53, 56 or 58, or a recombinantly  
produced invention DD-, DED-, or NB-ARC-containing protein,  
including naturally occurring allelic variants thereof  
encoded by mRNA generated by alternative splicing of a  
primary transcript, provided the DD-, DED-, or NB-ARC-  
30 containing proteins are not the sequence SEQ ID NOS:14, 24  
or 28. An invention DD- or DED-containing protein can

include SEQ ID NOS:16, 18, 20, or 22, or a protein containing a partial DD sequence such as SEQ ID NO:26. Preferably, a DD-, DED-, or NB-ARC-containing protein comprises an invention DD, DED or NB-ARC domain with a 5 sequence the same or substantially the same as SEQ ID NOS:2, 4, 6, 8, 10, 12, 53, 56 or 58, and can be the same or substantially the same sequence as SEQ ID NOS:18 or 22. More preferably, a DD-, DED-, or NB-ARC-containing protein comprises an invention DD, DED or NB-ARC with the sequence 10 of SEQ ID NOS:2, 4, 6, 8, 10, 12, 16, 18, 20, 22, 53, 56 or 58.

A DD-, DED-, NB-ARC-containing protein comprising an invention DD, DED or NB-ARC domain is further characterized as binding FADD, caspases such as caspase-8, 15 DR4, DR5, TRAF6, hToll, MyD88, or Fas proteins, or to modulate NF-κB activity or JNK activity; or modulating apoptosis, cell proliferation, cell adhesion, cell stress responses, responses to microbial infection, or B cell immunoglobulin class switching; or any combination thereof.

20 In another embodiment of the invention, DD-, DED-, or NB-ARC-containing chimeric proteins are provided comprising an invention DD, DED, or NB-ARC domain or fragments thereof, having the sequence of SEQ ID NOS:2, 4, 6, 8, 10, 12, 53, 56 or 58, and further comprising one or 25 more sequences from a heterologous protein. For example, an invention DD-DED- or NB-ARC domain can be fused to a RING finger domain, which has E3 activity. An F box protein can function to target Skp1-E3 complex for proteosome-dependent degradation (Tyers and Jorgensen, Curr. Opin. Genet. Dev. 30 10:54-64 (2000)). Invention DD-, DED-, or NB-ARC-containing

chimeric proteins include, for example, polypeptides having the sequence SEQ ID NOS:2, 4, 6, 8, 10, 12, 53, 56 or 58.

An invention chimeric protein can also comprise a portion of a polypeptide having the sequence SEQ ID NOS:18 or 22.

- 5 Sequences from heterologous proteins with which the DD, DED, or NB-ARC domain, or a functional fragment thereof, are fused will include, for example, glutathione-S-transferase, an antibody, or other proteins or functional fragments thereof which facilitate recovery of the chimera. Further,
- 10 proteins with which the DD, DED, or NB-ARC domain or functional fragment thereof, are fused will include, for example, luciferase, green fluorescent protein, an antibody, or other proteins or functional fragments thereof which facilitate identification of the chimera. Still further
- 15 proteins with which the DD, DED, or NB-ARC domain or functional fragment thereof, are fused will include, for example, the LexA DNA binding domain, ricin,  $\alpha$ -sarcin, an antibody, or other proteins which have therapeutic properties or other biological activity.

- 20 As such chimeric proteins include sequences from two different proteins, the resultant amino acid sequence of the chimeric protein will typically be a non-naturally occurring sequence. Thus, in accordance with this embodiment of the invention, there are provided chimeric
- 25 proteins comprising an invention DD, DED, or NB-ARC domain, or fragments thereof, having the sequence of SEQ ID NOS:2, 4, 6, 8, 10, 12, 53, 56 or 58, provided the sequence of the chimeric protein is not naturally occurring.

Further invention chimeric proteins contemplated herein are chimeric proteins wherein an invention DD, DED or NB-ARC is combined with one or more domains selected from apoptotic proteins from a heterologous protein.

5 Another embodiment of the invention provides DD, DED, or NB-ARC, or a functional fragment thereof, fused with a moiety to form a conjugate. As used herein, a "moiety" can be a physical, chemical or biological entity which contributes functionality to DD, DED or NB-ARC, or a  
10 functional fragment thereof. Functionalities contributed by a moiety include therapeutic or other biological activity, or the ability to facilitate identification or recovery of DD, DED or NB-ARC. Therefore, a moiety will include molecules known in the art to be useful for detection of the  
15 conjugate by, for example, by fluorescence, magnetic imaging, detection of radioactive emission, and the like. A moiety may also be useful for recovery of the conjugate, for example a His tag or other known tags used for protein isolation/purification, or a physical substance such as a  
20 bead. A moiety can be a therapeutic compound, for example, a cytotoxic drug which can be useful to effect a biological change in cells to which the conjugate localizes.

In accordance with another embodiment of the invention there are provided oligomers comprising invention  
25 DDs, DEDs, or NB-ARC domains and fragments thereof, invention DD-, DED-, or NB-ARC-containing proteins, DD-, DED-, or NB-ARC-containing chimeric proteins, or combinations thereof. In one embodiment, the invention comprises homo-oligomers of invention DDs, DEDs or NB-ARC  
30 domains and fragments thereof, invention DD-, DED- or NB-

ARC-containing proteins, DD-, DED- or NB-ARC-containing chimeric proteins, or combinations thereof.

In another embodiment of the invention, there are provided hetero-oligomers comprising invention DDs, DEDs, or 5 NB-ARC domains and fragments thereof, invention DD-, DED- or NB-ARC-containing proteins, DD-, DED- or NB-ARC-containing chimeric proteins, or combinations thereof. Thus hetero-oligomers comprising invention DDs, DEDs or NB-ARC domains and fragments thereof, invention DD-, DED- or NB-ARC- 10 containing proteins, DD-, DED- or NB-ARC-containing chimeric proteins, or combinations thereof, and further comprising FADD, caspases such as caspase-8, DR4, DR5, TRAF6, hToll, MyD88, and Fas, or combinations thereof. For example, the DAP3 DED (SEQ ID NO:2) can form a hetero-oligomer with FADD, 15 caspase-8, DR4, DR5, or combinations thereof. In another example, the IRAK4 DD (SEQ ID NO:6) can form a hetero-oligomer with TRAF6, hToll, MyD88, or combinations thereof. In a further example, the CTDD (SEQ ID NO:10) can form a hetero-oligomer with caspase-8, DR4, DR5, Fas, or 20 combinations thereof.

In accordance with another embodiment of the invention, there are provided isolated nucleic acids, which encode a novel DD, DED, or NB-ARC and fragments thereof, DD-, DED- or NB-ARC-containing proteins and DD-, DED- or 25 NB-ARC-containing chimeric proteins. Nucleic acids that encode a invention DD, DED or NB-ARC are those that encode a protein with the ability to bind, preferably *in vivo*, to one or more of FADD, caspases such as caspase-8, DR4, DR5, TRAF6, hToll, MyD88, and Fas, or any combination thereof, or 30 have the ability to modulate NF-κB activity, JNK activity,

apoptosis, cell proliferation, cell adhesion, cell stress responses, responses to microbial infection, or B cell immunoglobulin class switching. An invention nucleic acid encodes a DD, DED or NB-ARC domain having the sequence SEQ 5 ID NOS:2, 4, 6, 8, 10, 12, 53, 56 or 58, or a DD- or DED-containing polypeptide encoding SEQ ID NOS:16, 18, 20 or 22, or a polypeptide having SEQ ID NO:26.

The nucleic acid molecules described herein are useful for producing invention proteins, when such nucleic acids are incorporated into a variety of protein expression systems known to those of skill in the art. In addition, such nucleic acid molecules or fragments thereof can be labeled with a readily detectable substituent and used as hybridization probes for assaying for the presence and/or amount of an invention DD, DED or NB-ARC domain gene or mRNA transcript in a given sample. The nucleic acid molecules described herein, and fragments thereof, are also useful as primers and/or templates in a Polymerase Chain Reacion (PCR) for amplifying genes encoding invention proteins described herein.

The term "nucleic acid" (also referred to as polynucleotides) encompasses ribonucleic acid (RNA) or deoxyribonucleic acid (DNA), probes, oligonucleotides, and primers. DNA can be either complementary DNA (cDNA) or genomic DNA, e.g. a gene encoding a DD, DED or NB-ARC domain. In addition, a nucleic acid can be single-stranded, double-stranded, a sense strand or an anti-sense strand. One means of isolating a nucleic acid encoding a DD, DED, or NB-ARC domain or polypeptide is to probe a mammalian genomic library with a natural or artificially designed DNA probe

using methods well known in the art. DNA probes derived from the DD, DED or NB-ARC gene are particularly useful for this purpose. Oligonucleotides are useful, for example, as probes or as primers for amplification reactions such as the 5 polymerase chain reaction (PCR). DNA and cDNA molecules that encode DDs, DEDs or NB-ARC domain can be used to obtain complementary genomic DNA, cDNA or RNA from bacterial, eukaryotic (e.g., human, primate, mammal, plant, nematode, insect, yeast, and the like), or mammalian sources, or to 10 isolate related cDNA or genomic clones by the screening of cDNA or genomic libraries, by methods described in more detail below. Examples of nucleic acids are RNA, cDNA, or isolated genomic DNA encoding a DD, DED or NB-ARC domain, provided the nucleic acids do not comprise the nucleotide 15 sequence set forth in SEQ ID NOS:13, 23, 27, or 54 or nucleic acid encoding SEQ ID NO:57. The invention also provides nucleic acids referenced as SEQ ID NOS:15, 17, 19, 21 and 25. Such nucleic acids can include, but are not limited to, nucleic acids comprising the same or 20 substantially the same nucleotide sequence as set forth in SEQ ID NOS:1, 3, 5, 7, 9, 11 or 52.

In one embodiment of the present invention, cDNAs encoding the invention DD, DED or NB-ARC domain disclosed herein comprise the same or substantially the same 25 nucleotide sequence as set forth in SEQ ID NOS:1, 3, 5, 7, 9, 11, or 52, provided they do not comprise the sequence set forth in SEQ ID NO:13, 15, 19, 23, 25, 27, or 54, or a nucleic acid encoding SEQ ID NO:57. Preferred cDNA molecules encoding the invention proteins comprise the same 30 nucleotide sequence as set forth in SEQ ID NOS:1, 3, 5, 7, 9, 11 or 52.

In another embodiment of the present invention, cDNAs encoding the invention DDs, DEDs or NB-ARC domains disclosed herein comprise the same or substantially the same nucleotide sequence as set forth in SEQ ID NOS:1, 3, 5, 7, 9, 11 or 52. Preferred cDNA molecules encoding the invention proteins comprise the same nucleotide sequence as set forth in SEQ ID NOS:1, 3, 5, 7, 9, 11 or 52.

cDNA molecules SEQ ID NOS:1, 3, 5, 7, 9, 11 or 52 encoding the invention DD, DED or NB-ARC domains  
10 respectively represent the same nucleotide sequence as nucleotides 416-712 and 875-1084 set forth in SEQ ID NO:13; nucleotides 25-318 set forth in SEQ ID NO:15; nucleotides 268-462 set forth in SEQ ID NO:17; nucleotides 124-426 set forth in SEQ ID NO:19; nucleotides 418-630 set forth in SEQ  
15 ID NO:21.

As employed herein, the term "substantially the same nucleotide sequence" refers to DNA having sufficient identity to the reference polynucleotide, such that it will hybridize to the reference nucleotide under moderately stringent hybridization conditions. In one embodiment, DNA having substantially the same nucleotide sequence as the reference nucleotide sequence encodes substantially the same amino acid sequence as that set forth in any of SEQ ID NOS:2, 4, 6, 8, 10, 12, 18, 22, 53, 56 or 58, provided the  
20 DNA does not encode the sequence set forth in SEQ ID NOS:14, 24, 28, 55 or 57. In another embodiment, DNA having "substantially the same nucleotide sequence" as the reference nucleotide sequence has at least 60% identity with respect to the reference nucleotide sequence. DNA having at  
25 least 70%, more preferably at least 90%, yet more preferably  
30

at least 95%, identity to the reference nucleotide sequence is preferred. Identity of any two nucleic acid sequences can be determined by those skilled in the art based, for example, on a BLAST 2.0 computer alignment, using default parameters. BLAST 2.0 searching is available at <http://www.ncbi.nlm.nih.gov/gorf/bl2.html>., as described by Tatiana et al., FEMS Microbiol Lett. 174:247-250 (1999).

This invention also encompasses nucleic acids which differ from the nucleic acids shown in SEQ ID NOS:1, 10 3, 5, 7, 9, 11 and 52, but which have the same phenotype. Phenotypically similar nucleic acids are also referred to as "functionally equivalent nucleic acids". As used herein, the phrase "functionally equivalent nucleic acids" encompasses nucleic acids characterized by slight and non- 15 consequential sequence variations that will function in substantially the same manner to produce the same protein product(s) as the nucleic acids disclosed herein. In particular, functionally equivalent nucleic acids encode polypeptides that are the same as those encoded by the 20 nucleic acids disclosed herein or that have conservative amino acid variations. For example, conservative variations include substitution of a non-polar residue with another non-polar residue, or substitution of a charged residue with a similarly charged residue. These variations include those 25 recognized by skilled artisans as those that do not substantially alter the tertiary structure of the protein.

Further provided are nucleic acids encoding DDs, DEDs or NB-ARC domains that, by virtue of the degeneracy of the genetic code, do not necessarily hybridize to the 30 invention nucleic acids under specified hybridization

conditions. Preferred nucleic acids encoding the invention DDs, DEDs or NB-ARC domain are comprised of nucleotides that encode substantially the same amino acid sequence as set forth in SEQ ID NOS:2, 4, 6, 8, 10, 12, 18, 22, 53, 56 or 5 58, provided they do not encode the sequence set forth in SEQ ID NOS:14, 24, 28, 55 or 57.

Thus, an exemplary nucleic acid encoding an invention DD, DED, or NB-ARC can be selected from:

- 10 (a) DNA encoding the amino acid sequence set forth in SEQ ID NOS:2, 4, 6, 8, 10, 12, 53, 56 or 58;
- 15 (b) DNA that hybridizes to the DNA of (a) under moderately stringent conditions, wherein said DNA encodes biologically active DD, DED, or NB-ARC, or
- 20 (c) DNA degenerate with (b), wherein said DNA encodes biologically active DD, DED, or NB-ARC domain.

Another exemplary nucleic acid encoding an invention DD, DED or NB-ARC domain can be selected from:

- 25 (a) DNA encoding the amino acid sequence set forth in SEQ ID NOS:2, 4, 6, 8, 10, 12, 53, 56 or 58;
- (b) DNA that hybridizes to the DNA of (a) under moderately stringent conditions, wherein said DNA encodes biologically active DD, DED, or NB-ARC domain or
- 30 (c) DNA degenerate with (b), wherein said DNA encodes biologically active DD, DED, or NB-ARC domain, wherein the nucleic acid sequence does not

encode the amino acid sequence set forth in SEQ ID NOS:14, 24, 28, 55 or 57.

The invention additionally provides an isolated nucleic acid encoding a Death Domain (DD), Death Effector 5 Domain (DED) or NB-ARC domain polypeptide, or functional fragments thereof, the nucleic acid encoding the amino acid sequence set forth in SEQ ID NOS:2, 4, 6, 8, 10, 12, 16, 18, 20, 22, 26, 53, 56 or 58. The invention also provides a nucleic acid having the same or substantially the same 10 sequence as set forth in any of SEQ ID NOS:1, 3, 5, 7, 9, 11, 17, 21 or 52. The invention also provides a nucleic acid having the same sequence as that set forth in any of SEQ ID NOS:1, 3, 5, 7, 9, 11, 15, 17, 19, 21, 25 or 52.

Hybridization refers to the binding of 15 complementary strands of nucleic acid (i.e., sense:antisense strands or probe:target-DNA) to each other through hydrogen bonds, similar to the bonds that naturally occur in chromosomal DNA. Stringency levels used to hybridize a given probe with target-DNA can be readily varied by those 20 of skill in the art.

The phrase "stringent hybridization" is used herein to refer to conditions under which polynucleic acid hybrids are stable. As known to those of skill in the art, the stability of hybrids is reflected in the melting 25 temperature ( $T_m$ ) of the hybrids. In general, the stability of a hybrid is a function of sodium ion concentration and temperature. Typically, the hybridization reaction is performed under conditions of lower stringency, followed by

washes of varying, but higher, stringency. Reference to hybridization stringency relates to such washing conditions.

As used herein, the phrase "moderately stringent hybridization" refers to conditions that permit target-DNA 5 to bind a complementary nucleic acid that has about 60% identity, preferably about 75% identity, more preferably about 85% identity to the target DNA; with greater than about 90% identity to target-DNA being especially preferred. Preferably, moderately stringent conditions are conditions 10 equivalent to hybridization in 50% formamide, 5X Denhart's solution, 5X SSPE, 0.2% SDS at 42°C, followed by washing in 0.2X SSPE, 0.2% SDS, at 42°C.

The phrase "high stringency hybridization" refers to conditions that permit hybridization of only those 15 nucleic acid sequences that form stable hybrids in 0.018M NaCl at 65°C (i.e., if a hybrid is not stable in 0.018M NaCl at 65°C, it will not be stable under high stringency conditions, as contemplated herein). High stringency conditions can be provided, for example, by hybridization in 20 50% formamide, 5X Denhart's solution, 5X SSPE, 0.2% SDS at 42°C, followed by washing in 0.1X SSPE, and 0.1% SDS at 65°C.

The phrase "low stringency hybridization" refers to conditions equivalent to hybridization in 10% formamide, 25 5X Denhart's solution, 6X SSPE, 0.2% SDS at 42°C, followed by washing in 1X SSPE, 0.2% SDS, at 50°C. Denhart's solution and SSPE (see, e.g., Sambrook et al., *supra*, 1989) are well known to those of skill in the art as are other suitable hybridization buffers.

As used herein, the term "degenerate" refers to codons that differ in at least one nucleotide from a reference nucleic acid, e.g., SEQ ID NOS:1, 3, 5, 7, 9, 11 or 52, but encode the same amino acids as the reference nucleic acid. For example, codons specified by the triplets "UCU", "UCC", "UCA", and "UCG" are degenerate with respect to each other since all four of these codons encode the amino acid serine.

Preferred nucleic acids encoding the invention polypeptide(s) hybridize under moderately stringent, preferably high stringency, conditions to substantially the entire sequence, or substantial portions (i.e., typically at least 15-30 nucleotides) of the nucleic acid sequence set forth in SEQ ID NOS:1, 3, 5, 7, 9, 11, 52, provided they do not comprise the sequence set forth in SEQ ID NOS:13, 23, 27 or 54, or a nucleic acid encoding SEQ ID NO:57.

The invention nucleic acids can be produced by a variety of methods well-known in the art, e.g., the methods described herein, employing PCR amplification using oligonucleotide primers from various regions of SEQ ID NOS:1, 3, 5, 7, 9, 11 or 52, and the like.

In accordance with a further embodiment of the present invention, optionally labeled DD, DED or NB-ARC encoding cDNAs, or fragments thereof, can be employed to probe library(ies) (e.g., cDNA, genomic, and the like) for additional nucleic acid sequences encoding novel bacterial or eukaryotic DD, DED or NB-ARC domains. Construction of suitable bacterial libraries or eukaryotic cDNA libraries is

well-known in the art. Screening of such a cDNA library is initially carried out under low-stringency conditions, which comprise a temperature of less than about 42°C, a formamide concentration of less than about 50%, and a moderate to low  
5 salt concentration.

Presently preferred probe-based screening conditions comprise a temperature of about 37°C, a formamide concentration of about 20%, and a salt concentration of about 5X standard saline citrate (SSC; 20X SSC contains 3M  
10 sodium chloride, 0.3M sodium citrate, pH 7.0). Such conditions will allow the identification of sequences which have a substantial degree of similarity with the probe sequence, without requiring perfect homology. The phrase "substantial similarity" refers to sequences which share at  
15 least 50% homology. Preferably, hybridization conditions will be selected which allow the identification of sequences having at least 70% homology, at least 80%, at least 90%, at least 95%, or at least 98% with the probe, while discriminating against sequences which have a lower degree  
20 of homology with the probe. As a result, nucleic acids having the same or substantially the same nucleotide sequence as SEQ ID NOS:13, 15, 17, 19, 21, 25, 27 or 54 are obtained.

As used herein, a nucleic acid "probe" or  
25 "oligonucleotide" is single-stranded or double-stranded DNA or RNA, or analogs thereof, that has a sequence of nucleotides that includes at least 15, at least 20, at least 50, at least 100, at least 200, at least 300, at least 400, or at least 500 contiguous bases that are the same as (or  
30 the complement of) any contiguous bases set forth in any of

SEQ ID NOS:1, 3, 5, 7, 9, 11, 15, 17, 19, 21 or 52.

Oligonucleotides are useful, for example, as probes or as primers for amplification reactions such as the polymerase chain reaction (PCR). In addition, oligonucleotides can bind to the sense or anti-sense strands of other nucleic acids. Preferred regions from which to construct probes include 5' and/or 3' coding regions of SEQ ID NOS:1, 3, 5, 7, 9, 11, 15, 17, 19, 21 or 52. In addition, the entire cDNA encoding region of an invention DD, DED, or NB-ARC domain or the entire sequence corresponding to SEQ ID NOS:1, 3, 5, 7, 9, 11, 15, 17, 19, 21 or 52 can be used as a probe. Probes can be labeled by methods well-known in the art, as described hereinafter, and used in various diagnostic kits.

It is understood that an invention nucleic acid molecule, as used herein, specifically excludes previously known nucleic acid molecules consisting of nucleotide sequences having identity with the DD, DED and NB-ARC nucleotide sequence, such as Expressed Sequence Tags (ESTs), Sequence Tagged Sites (STSs) and genomic fragments, deposited in public databases such as the nr, dbest, dbsts, gss and htgs databases, which are available for searching at <http://www.ncbi.nlm.nih.gov/blast/blast.cgi?Jform=0>, using the program BLASTN 2.0.9 described by Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997).

In particular, a DD, DED or NB-ARC domain nucleic acid molecule specifically excludes nucleic acid molecules consisting of any of the nucleotide sequences having the Genbank (gb), EMBL (emb) or DDBJ (dbj) accession numbers described below. Similarly, a DD, DED or NB-ARC domain polypeptide fragment of DD, DED or NB-ARC domain containing-

polypeptide specifically excludes the amino acid fragments encoded by the nucleotide sequences having the GenBank accession numbers described below. GenBank accession numbers specifically excluded include AW449244, AA218681, GI 5 4210498, GI 1832773, GI 6990020, GI 4758118 (accession No. NP\_004623), X83544, GI 7705841, GI 7705840, GI 5360131 (locus AF155118, accession No. AAD42884), AA114228, BE797255, BE242821, AW229739, AW227145, AV149215, GI 7190927, GI 7468151, GI 5353348, GI 4607778, and GI 6960635.

10 As used herein, the terms "label" and "indicating means" in their various grammatical forms refer to single atoms and molecules that are either directly or indirectly involved in the production of a detectable signal. Any label or indicating means can be linked to invention nucleic 15 acid probes, expressed proteins, polypeptide fragments, or antibody molecules. These atoms or molecules can be used alone or in conjunction with additional reagents. Such labels are themselves well-known in clinical diagnostic chemistry.

20 The labeling means can be a fluorescent labeling agent that chemically binds to antibodies or antigens without denaturation to form a fluorochrome (dye) that is a useful immunofluorescent tracer. A description of immunofluorescent analytic techniques is found in DeLuca, 25 "Immunofluorescence Analysis", in Antibody As a Tool, Marchalonis et al., eds., John Wiley & Sons, Ltd., pp. 189-231 (1982), which is incorporated herein by reference.

In one embodiment, the indicating group is an enzyme, such as horseradish peroxidase (HRP), glucose oxidase, and the like. In another embodiment, radioactive elements are employed as labeling agents. The linking of a 5 label to a substrate, i.e., labeling of nucleic acid probes, antibodies, polypeptides, and proteins, is well known in the art. Detectable labels can be incorporated by chemical synthesis, chemical modification, *in vitro* enzymatic incorporation, or *in vivo* metabolic labeling. For instance, 10 an invention antibody can be labeled by metabolic incorporation of radiolabeled amino acids provided in the culture medium. See, for example, Galfre et al., Meth. Enzymol., 73:3-46 (1981). Conventional means of protein conjugation or coupling by activated functional groups are 15 particularly applicable. See, for example, Aurameas et al., Scand. J. Immunol., Vol. 8, Suppl. 7:7-23 (1978), Rodwell et al., Biotech., 3:889-894 (1984), and U.S. Patent No. 4,493,795.

In another embodiment of the invention, nucleic 20 acids are provided encoding chimeric proteins comprising an invention DD, DED, or NB-ARC domain or fragment thereof, having the sequence of SEQ ID NOS:2, 4, 6, 8, 10, 12, 53, 56 or 58, and further comprising one or more sequences from a heterologous protein. Functional fragments of DD, DED or 25 NB-ARC include, for example, polypeptides having the sequence SEQ ID NO:2, 4, 6, 8, 10, 12, 53, 56 or 58. Nucleic acids encoding proteins with which the DD, DED or NB-ARC domain, or functional fragment thereof, are fused will also encode, for example, glutathione-S-transferase, an 30 antibody, or other proteins or functional fragments thereof which facilitate recovery of the chimera. Nucleic acids of

the invention can also encode proteins with which the DD, DED, or NB-ARC domain, or functional fragment thereof, are fused, for example, to luciferase, green fluorescent protein, an antibody, or other proteins or functional fragments thereof which facilitate identification of the chimera. Still further nucleic acids of the invention encode proteins with which the DD, DED or NB-ARC domain or functional fragment thereof are fused including, for example, the LexA DNA binding domain, ricin,  $\alpha$ -sarcin, an antibody, or other proteins which have therapeutic properties or other biological activity.

The present invention also provides compositions containing an acceptable carrier and any of an isolated, purified DD-, DED- or NB-ARC-containing protein or functional polypeptide fragments thereof, alone or in combination with each other. These polypeptides or proteins can be recombinantly derived, chemically synthesized or purified from native sources. As used herein, the term "acceptable carrier" encompasses any of the standard pharmaceutical carriers, such as phosphate buffered saline solution, water and emulsions such as an oil/water or water/oil emulsion, and various types of wetting agents.

The DD, DED or NB-ARC compositions described herein can be used, for example, in methods for modulating the activity of members of the apoptotic pathway. Thus it is within the scope of the present invention that a protein comprising the sequence SEQ ID NOS:2, 4, 6, 8, 10, 12, 53, 56 or 58 or a nucleic acid encoding a protein comprising the sequence SEQ ID NOS:1, 3, 5, 7, 9, 11 or 52, modulates the activity of member of an apoptotic pathway.

In one embodiment, modulation of a member of FADD, caspases such as caspase-8 and caspase-10, DR4, DR5, Traf6, hToll, MyD88, Fas, Raidd, IRAK, IRAK-2, IRAK-M, p75NTR, Tradd, DAP kinase, RIP, NMP84, ankyrins, Flip, PEA15, Flash, 5 BAP31, BAR, DEDT/DEDD, and DAP3 or a related polypeptide that binds an invention DD, DED or NB-ARC will comprise the step of contacting a member of FADD, caspases such as caspase-8 and caspase-10, DR4, DR5, Traf6, hToll, MyD88, Fas, Raidd, IRAK, IRAK-2, IRAK-M, p75NTR, Tradd, DAP kinase, 10 RIP, NMP84, ankyrins, Flip, PEA15, Flash, BAP31, BAR, DEDT/DEDD, and DAP3 with a protein comprising the sequence SEQ ID NOS:2, 4, 6, 8, 10, 12, 16, 18, 20, 22, 26, 53, 56 or 58. Preferably, the method comprises contacting a cell with a protein comprising the sequence of SEQ ID NOS:2, 4, 6, 8, 15 10, 12, 53, 56 or 58.

In another embodiment, modulation of a member of FADD, caspases such as caspase-8 and caspase-10, DR4, DR5, Traf6, hToll, MyD88, Fas, Raidd, IRAK, IRAK-2, IRAK-M, p75NTR, Tradd, DAP kinase, RIP, NMP84, ankyrins, Flip, 20 PEA15, Flash, BAP31, BAR, DEDT/DEDD, and DAP3, or a related polypeptide that binds an invention DD, DED, or NB-ARC will comprise the step of contacting a member of FADD, caspases such as caspase-8 and caspase-10, DR4, DR5, Traf6, hToll, MyD88, Fas, Raidd, IRAK, IRAK-2, IRAK-M, p75NTR, Tradd, DAP 25 kinase, RIP, NMP84, ankyrins, Flip, PEA15, Flash, BAP31, BAR, DEDT/DEDD, and DAP3 or a related polypeptide that binds an invention DD, DED or NB-ARC domain, with a nucleic acid encoding a protein comprising the sequence SEQ ID NOS:2, 4, 6, 8, 10, 12, 16, 18, 20, 22, 26, 53, 56 or 58. Preferably, 30 the method comprises contacting a cell with a nucleic acid

encoding a protein comprising the sequence of SEQ ID NOS:2, 4, 6, 8, 10, 12, 16, 18, 20, 22, 26, 53, 56 or 58.

In another embodiment, the DD, DED or NB-ARC domain compositions described herein can be used, for example, in methods for modulating the activity of proteins containing domains that bind invention DDs, DEDs or NB-ARC domains. Thus, it is within the scope of the present invention that a protein comprising the sequence SEQ ID NOS:2, 4, 6, 8, 10, 12, 16, 18, 20, 22, 26, 53, 56 or 58, or a nucleic acid encoding a protein comprising the sequence SEQ ID NOS:2, 4, 6, 8, 10, 12, 16, 18, 20, 22, 26, 53, 56 or 58, modulates the activity of one or more proteins containing domains that bind invention DDs, DEDs or NB-ARC domains.

In one embodiment, modulation of a protein containing a domain that interacts with an invention DD, DED or NB-ARC domain will comprise the step of contacting a protein containing a domain that interacts with an invention DD, DED or NB-ARC domain with a protein comprising the sequence SEQ ID NOS:2, 4, 6, 8, 10, 12, 16, 18, 20, 22, 26, 53, 56 or 58. Preferably, the method comprises contacting a cell with a protein comprising the sequence of SEQ ID NOS:2, 4, 6, 8, 10, 12, 16, 18, 20, 22, 26, 53, 56 or 58.

In another embodiment, modulation of a protein containing a domain that interacts with an invention DD, DED or NB-ARC will comprise the step of contacting a protein containing a domain that interacts with an invention DD, DED or NB-ARC with a nucleic acid encoding a protein comprising the sequence SEQ ID NOS:2, 4, 6, 8, 10, 12, 16, 18, 20, 22,

26, 53, 56 or 58. Preferably, the method comprises contacting a cell with a nucleic acid encoding a protein comprising the sequence of SEQ ID NOS:2, 4, 6, 8, 10, 12, 16, 18, 20, 22, 26, 53, 56 or 58.

5           In another embodiment, a DD, DED or NB-ARC domain comprising the sequence SEQ ID NOS:2, 4, 6, 8, 10, 12, 16, 18, 20, 22, 26, 53, 56 or 58, or a nucleic acid encoding a protein comprising the sequence SEQ ID NOS:2, 4, 6, 8, 10, 12, 16, 18, 20, 22, 26, 53, 56 or 58, modulates the activity  
10 of one or more associated proteins. Thus it is within the scope of the invention that an invention DD, DED or NB-ARC domain protein can modulate the activity of any protein with which the DD, DED or NB-ARC domain proteins are known to interact.

15           In one embodiment, modulation of a protein that binds an invention DD, DED or NB-ARC domain will comprise the step of contacting a with a protein comprising the sequence SEQ ID NOS:2, 4, 6, 8, 10, 12, 16, 18, 20, 22, 26, 53, 56 or 58. Preferably, the method comprises contacting a  
20 cell with a protein comprising the sequence of SEQ ID NOS:2, 4, 6, 8 10, 12, 16, 18, 20, 22, 26, 53, 56 or 58.

              In another embodiment, modulation of a protein that interacts with an invention DD, DED or NB-ARC will comprise the step of contacting a protein that interacts  
25 with an invention DD, DED or NB-ARC with a nucleic acid encoding a protein comprising the sequence SEQ ID NOS:2, 4, 6, 8, 10, 12, 16, 18, 20, 22, 26, 53, 56 or 58. Preferably, the method comprises contacting a cell with a nucleic acid

encoding a protein comprising the sequence of SEQ ID NOS:2, 4, 6, 8, 10, 12, 16, 18, 20, 22, 26, 53, 56 or 58.

DD or NB-ARC domain compositions can also be used, for example, in methods for modulating the activity of NF-  
5 kB or JNK. Proteins homologous to invention DD or NB-ARC domain, for example, the DD of IRAK4 (SEQ ID NO:6) is shown herein to modulate NF- $\kappa$ B activity. An invention NB-ARC domain, for example, the NB-ARC domain of DAP3, is expected to modulated NF $\kappa$ B activity based on previously known  
10 regulation of NF $\kappa$ B by the NB-ARC protein Nod1/CARD4. Thus, in accordance with another embodiment of the invention, a protein comprising the sequence SEQ ID NOS:2, 4, 6, 10, 12, 53, 56 or 58, or a nucleic acid encoding a protein comprising the sequence SEQ ID NOS:2, 4, 6, 10, 12, 53, 56  
15 or 58, modulates the activity of NF- $\kappa$ B or JNK.

In one embodiment, modulation of NF- $\kappa$ B or JNK activity will comprise the step of contacting a cell containing NF- $\kappa$ B activity with a protein comprising the sequence SEQ ID NO:2, 4, 6, 10, 12, 53, 56 or 58.  
20 Preferably, the method comprises contacting a cell with a protein comprising the sequence of SEQ ID NO:2, 4, 6, 10, 12, 53, 56 or 58.

In another embodiment, modulation of NF- $\kappa$ B or JNK activity will comprise the step of contacting a cell containing NF- $\kappa$ B activity or JNK activity with a nucleic acid encoding a protein comprising the sequence SEQ ID NO:2, 4, 6, 10, 12, 53, 56 or 58. Preferably, the method comprises contacting a cell with a nucleic acid encoding a

protein comprising the sequence of SEQ ID NO:2, 4, 6, 10, 12, 53, 56 or 58.

As disclosed herein, the N-terminal domain of DAP3 binds caspase-8, and DAP3 increases caspase-8 protease activity. Therefore, in another embodiment, modulation of caspase-8 activity comprises the step of contacting a cell containing caspase-8 activity with a nucleic acid encoding a protein comprising the NB-ARC domain (SEQ ID NO:4) of DAP3, or an invention DD- or DED-containing polypeptide.

The functions of the invention DDs, DEDs and NB-ARC domains support the role of DD, DED and NB-ARC domain containing polypeptides in modulating cellular pathways that effect apoptosis, cell proliferation, cell adhesion, cell stress responses, responses to microbial infection, and B cell immunoglobulin class switching. Thus, in accordance with another embodiment of the invention, a protein comprising the sequence SEQ ID NOS:2, 4, 6, 8, 10, 12, 53, 56 or 58, or SEQ ID NOS:16, 18, 20, 22 or 26, or a nucleic acid encoding a protein comprising the sequence SEQ ID NOS:2, 4, 6, 8, 10, 12, 53, 56 or 58, or SEQ ID NOS:16, 18, 20, 22 or 26, modulates apoptosis, cell proliferation, cell adhesion, cell stress responses, responses to microbial infection, or B cell immunoglobulin class switching.

In one embodiment, modulation of apoptosis, cell proliferation, cell adhesion, cell stress responses, responses to microbial infection, or B cell immunoglobulin class switching will comprise the step of contacting a cell with a protein comprising the sequence SEQ ID NOS:2, 4, 6, 8, 10, 12, 53, 56 or 58, or SEQ ID NOS:16, 18, 20, 22 or 26,

whereby apoptosis, cell proliferation, cell adhesion, cell stress responses, responses to microbial infection, or B cell immunoglobulin class switching is modulated.

Preferably, the method comprises contacting a cell with a  
5 protein comprising the sequence of SEQ ID NOS:2, 4, 6, 8,  
10, 12, 53, 56 or 58, or SEQ ID NOS:16, 18, 20, 22 or 26.

In another embodiment, modulation of apoptosis, cell proliferation, cell adhesion, cell stress responses, responses to microbial infection, or B cell immunoglobulin  
10 class switching will comprise the step of contacting a cell with a nucleic acid encoding a protein comprising the sequence SEQ ID NOS:2, 4, 6, 8, 10, 12, 53, 56 or 58, or SEQ ID NOS:16, 18, 20, 22 or 26, whereby apoptosis, cell proliferation, cell adhesion, cell stress responses,  
15 responses to microbial infection, or B cell immunoglobulin class switching is modulated. Preferably, the method comprises contacting a cell with a nucleic acid encoding a protein comprising the sequence of SEQ ID NO:2, 4, 6, 8, 10,  
12, 53, 56 or 58, or SEQ ID NOS:16, 18, 20, 22 or 26.

20           Also provided are antisense-nucleic acids having a sequence capable of binding specifically with full-length or any portion of an mRNA that encodes DD, DED or NB-ARC domain polypeptides so as to prevent translation of the mRNA. The antisense-nucleic acid can have a sequence capable of  
25 binding specifically with any portion of the sequence of the cDNA encoding DD, DED or NB-ARC domain polypeptides. As used herein, the phrase "binding specifically" encompasses the ability of a nucleic acid sequence to recognize a complementary nucleic acid sequence and to form double-  
30 helical segments therewith via the formation of hydrogen

bonds between the complementary base pairs. An example of an antisense-nucleic acid is an antisense-nucleic acid comprising chemical analogs of nucleotides. Exemplary antisense molecules for the DED containing polypeptide DAP3  
5 are described herein.

Compositions comprising an amount of the antisense-nucleic acid, described above, effective to reduce expression of DD, DED or NB-ARC domain polypeptides by passing through a cell membrane and binding specifically  
10 with mRNA encoding DD, DED or NB-ARC domain polypeptides so as to prevent translation and an acceptable hydrophobic carrier capable of passing through a cell membrane are also provided herein. Suitable hydrophobic carriers are described, for example, in U.S. Patent Nos. 5,334,761;  
15 4,889,953; 4,897,355, and the like. The acceptable hydrophobic carrier capable of passing through cell membranes may also comprise a structure which binds to a receptor specific for a selected cell type and is thereby taken up by cells of the selected cell type. The structure  
20 may be part of a protein known to bind to a cell-type specific receptor.

Antisense-nucleic acid compositions are useful to inhibit translation of mRNA encoding invention polypeptides. Synthetic oligonucleotides, or other antisense chemical  
25 structures are designed to bind to mRNA encoding DD, DED or NB-ARC domain polypeptides and inhibit translation of mRNA and are useful as compositions to inhibit expression of DD, DED or NB-ARC domain associated genes in a tissue sample or in a subject.

In accordance with another embodiment of the invention, kits for detecting mutations, duplications, deletions, rearrangements and aneuploidies in DD, DED or NB-ARC genes comprising at least one invention probe or  
5 antisense nucleotide.

The present invention provides means to modulate levels of expression of DD, DED or NB-ARC polypeptides by employing synthetic antisense-nucleic acid compositions (hereinafter SANC) which inhibit translation of mRNA  
10 encoding these polypeptides. Synthetic oligonucleotides, or other antisense-nucleic acid chemical structures designed to recognize and selectively bind to mRNA, are constructed to be complementary to full-length or portions of a DD, DED or NB-ARC domain coding strand, including nucleotide sequences  
15 set forth in SEQ ID NOS:1, 3, 5, 7, 9, 11, 17, 21 or 52. The SANC is designed to be stable in the blood stream for administration to a subject by injection, or in laboratory cell culture conditions. The SANC is designed to be capable of passing through the cell membrane in order to enter the  
20 cytoplasm of the cell by virtue of physical and chemical properties of the SANC which render it capable of passing through cell membranes, for example, by designing small, hydrophobic SANC chemical structures, or by virtue of specific transport systems in the cell which recognize and  
25 transport the SANC into the cell. In addition, the SANC can be designed for administration only to certain selected cell populations by targeting the SANC to be recognized by specific cellular uptake mechanisms which bind and take up the SANC only within select cell populations. In a  
30 particular embodiment the SANC is an antisense oligonucleotide.

For example, the SANC may be designed to bind to a receptor found only in a certain cell type, as discussed *supra*. The SANC is also designed to recognize and selectively bind to target mRNA sequence, which may 5 correspond to a sequence contained within the sequences shown in SEQ ID NOS:1, 3, 5, 7, 9, 11, 17, 21 or 52. The SANC is designed to inactivate target mRNA sequence by either binding thereto and inducing degradation of the mRNA by, for example, RNase I digestion, or inhibiting 10 translation of mRNA target sequence by interfering with the binding of translation-regulating factors or ribosomes, or inclusion of other chemical structures, such as ribozyme sequences or reactive chemical groups which either degrade or chemically modify the target mRNA. SANCs have been shown 15 to be capable of such properties when directed against mRNA targets (see Cohen et al., TIPS, 10:435 (1989) and Weintraub, Sci. American, January (1990), pp.40; both incorporated herein by reference).

In accordance with yet another embodiment of the 20 present invention, there is provided a method for the recombinant production of invention DDs, DEDs or NB-ARC domains by expressing the above-described nucleic acid sequences in suitable host cells. Recombinant DNA expression systems that are suitable to produce DDs, DEDs or 25 NB-ARC domains described herein are well-known in the art. For example, the above-described nucleotide sequences can be incorporated into vectors for further manipulation. As used herein, vector (or plasmid) refers to discrete elements that are used to introduce heterologous DNA into cells for either 30 expression or replication thereof.

Suitable expression vectors are well-known in the art, and include vectors capable of expressing DNA operatively linked to a regulatory sequence, such as a promoter region that is capable of regulating expression of such DNA. Thus, an expression vector refers to a recombinant DNA or RNA construct, such as a plasmid, a phage, recombinant virus or other vector that, upon introduction into an appropriate host cell, results in expression of the inserted DNA. Appropriate expression vectors are well known to those of skill in the art and include those that are replicable in eukaryotic cells and/or prokaryotic cells and those that remain episomal or those which integrate into the host cell genome.

As used herein, a promoter region refers to a segment of DNA that controls transcription of DNA to which it is operatively linked. The promoter region includes specific sequences that are sufficient for RNA polymerase recognition, binding and transcription initiation. In addition, the promoter region includes sequences that modulate this recognition, binding and transcription initiation activity of RNA polymerase. These sequences may be *cis* acting or may be responsive to *trans* acting factors. Promoters, depending upon the nature of the regulation, may be constitutive or regulated. Exemplary promoters contemplated for use in the practice of the present invention include the SV40 early promoter, the cytomegalovirus (CMV) promoter, the mouse mammary tumor virus (MMTV) steroid-inducible promoter, Moloney murine leukemia virus (MMLV) promoter, and the like.

As used herein, the term "operatively linked" refers to the functional relationship of DNA with regulatory and effector nucleotide sequences, such as promoters, enhancers, transcriptional and translational stop sites, and other signal sequences. For example, operative linkage of DNA to a promoter refers to the physical and functional relationship between the DNA and the promoter such that the transcription of such DNA is initiated from the promoter by an RNA polymerase that specifically recognizes, binds to and transcribes the DNA.

As used herein, expression refers to the process by which polynucleic acids are transcribed into mRNA and translated into peptides, polypeptides, or proteins. If the polynucleic acid is derived from genomic DNA, expression can, if an appropriate eukaryotic host cell or organism is selected, include splicing of the mRNA.

Prokaryotic transformation vectors are well-known in the art and include pBlueskript and phage Lambda ZAP vectors (Stratagene, La Jolla, CA), and the like. Other suitable vectors and promoters are disclosed in detail in U.S. Patent No. 4,798,885, issued January 17, 1989, the disclosure of which is incorporated herein by reference in its entirety.

Other suitable vectors for transformation of *E. coli* cells include the pET expression vectors (Novagen, see U.S patent 4,952,496), e.g., pET11a, which contains the T7 promoter, T7 terminator, the inducible *E. coli* lac operator, and the lac repressor gene; and pET 12a-c, which contain the T7 promoter, T7 terminator, and the *E. coli* ompT

secretion signal. Another suitable vector is the pIN-IIIompA2 (see Duffaud et al., Meth. in Enzymology, 153:492-507, 1987), which contains the lpp promoter, the lacUV5 promoter operator, the ompA secretion signal, and the lac repressor gene.

Exemplary, eukaryotic transformation vectors, include the cloned bovine papilloma virus genome, the cloned genomes of the murine retroviruses, and eukaryotic cassettes, such as the pSV-2 gpt system (described by 10 Mulligan and Berg, Nature Vol. 277:108-114 (1979)] the Okayama-Berg cloning system (Mol. Cell Biol. 2:161-170 (1982)), and the expression cloning vector described by Genetics Institute (Wong et al., Science 228:810-815 (1985)), are available which provide substantial assurance 15 of at least some expression of the protein of interest in the transformed eukaryotic cell line.

Particularly preferred base vectors which contain regulatory elements that can be linked to the invention DD-, DED- or NB-ARC domain-encoding DNAs for transfection of 20 mammalian cells are cytomegalovirus (CMV) promoter-based vectors such as pcDNA1 (Invitrogen, San Diego, CA), MMTV promoter-based vectors such as pMAMNeo (Clontech, Palo Alto, CA) and pMSG (Pharmacia, Piscataway, NJ), and SV40 promoter-based vectors such as pSV $\beta$  (Clontech, Palo Alto, CA).

25 In accordance with another embodiment of the present invention, there are provided "recombinant cells" containing the nucleic acid molecules (i.e., DNA or mRNA) of the present invention. Methods of transforming suitable host cells, preferably bacterial cells, and more preferably

*E. coli* cells, as well as methods applicable for culturing said cells containing a gene encoding a heterologous protein, are generally known in the art. See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual (2 ed.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, USA (1989).

Exemplary methods of transformation include, e.g., transformation employing plasmids, viral, or bacterial phage vectors, transfection, electroporation, lipofection, and the like. The heterologous DNA can optionally include sequences which allow for its extrachromosomal maintenance, or said heterologous DNA can be caused to integrate into the genome of the host (as an alternative means to ensure stable maintenance in the host).

Host organisms contemplated for use in the practice of the present invention include those organisms in which recombinant production of heterologous proteins has been carried out. Examples of such host organisms include bacteria (e.g., *E. coli*), yeast (e.g., *Saccharomyces cerevisiae*, *Candida tropicalis*, *Hansenula polymorpha* and *P. pastoris*; see, e.g., U.S. Patent Nos. 4,882,279, 4,837,148, 4,929,555 and 4,855,231), mammalian cells (e.g., HEK293, CHO and Ltk<sup>-</sup> cells), insect cells, and the like. Presently preferred host organisms are bacteria. The most preferred bacteria is *E. coli*.

In one embodiment, nucleic acids encoding the invention DDs, DEDs or NB-ARC domains can be delivered into mammalian cells, either *in vivo* or *in vitro* using suitable viral vectors well-known in the art. Suitable retroviral

vectors, designed specifically for "gene therapy" methods, are described, for example, in WIPO publications WO 9205266 and WO 9214829, which provide a description of methods for efficiently introducing nucleic acids into human cells. In 5 addition, where it is desirable to limit or reduce the *in vivo* expression of the invention DD-, DED- or NB-ARC domain-containing, the introduction of the antisense strand of the invention nucleic acid is contemplated.

Viral based systems provide the advantage of being 10 able to introduce relatively high levels of the heterologous nucleic acid into a variety of cells. Suitable viral vectors for introducing invention nucleic acid encoding an DD, DED or NB-ARC domain into mammalian cells (e.g., vascular tissue segments) are well known in the art. These 15 viral vectors include, for example, Herpes simplex virus vectors (e.g., Geller et al., Science, 241:1667-1669 (1988)), Vaccinia virus vectors (e.g., Piccini et al., Meth. in Enzymology, 153:545-563 (1987); Cytomegalovirus vectors (Mocarski et al., in Viral Vectors, Y. Gluzman and S.H. 20 Hughes, Eds., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1988, pp. 78-84), Moloney murine leukemia virus vectors (Danos et al., PNAS, USA, 85:6469 (1980)), adenovirus vectors (e.g., Logan et al., PNAS, USA, 81:3655- 25 3659 (1984); Jones et al., Cell, 17:683-689 (1979); Berkner, Biotechniques, 6:616-626 (1988); Cotten et al., PNAS, USA, 89:6094-6098 (1992); Graham et al., Meth. Mol. Biol., 7:109- 30 127 (1991)), adeno-associated virus vectors, retrovirus vectors (see, e.g., U.S. Patent 4,405,712 and 4,650,764), and the like. Especially preferred viral vectors are the adenovirus and retroviral vectors.

For example, in one embodiment of the present invention, adenovirus-transferrin/polylysine-DNA (TfAdpl-DNA) vector complexes (Wagner et al., PNAS, USA, 89:6099-6103 (1992); Curiel et al., Hum. Gene Ther., 3:147-5 154 (1992); Gao et al., Hum. Gene Ther., 4:14-24 (1993)) are employed to transduce mammalian cells with heterologous DD, DED or NB-ARC domain nucleic acid. Any of the plasmid expression vectors described herein may be employed in a TfAdpl-DNA complex.

10 As used herein, "retroviral vector" refers to the well-known gene transfer plasmids that have an expression cassette encoding an heterologous gene residing between two retroviral LTRs. Retroviral vectors typically contain appropriate packaging signals that enable the retroviral  
15 vector, or RNA transcribed using the retroviral vector as a template, to be packaged into a viral virion in an appropriate packaging cell line (see, e.g., U.S. Patent 4,650,764).

Suitable retroviral vectors for use herein are  
20 described, for example, in U.S. Patent 5,252,479, and in WIPO publications WO 92/07573, WO 90/06997, WO 89/05345, WO 92/05266 and WO 92/14829, incorporated herein by reference, which provide a description of methods for efficiently introducing nucleic acids into human cells using such  
25 retroviral vectors. Other retroviral vectors include, for example, the mouse mammary tumor virus vectors (e.g., Shackleford et al., PNAS, USA, 85:9655-9659 (1988)), and the like.

In accordance with yet another embodiment of the present invention, there are provided anti-DD, anti-DED or anti-NB-ARC domain antibodies having specific reactivity with one or more DD, DED or NB-ARC polypeptides of the 5 present invention. Active fragments of antibodies are encompassed within the definition of "antibody". Invention antibodies can be produced by methods known in the art using invention polypeptides, proteins or portions thereof as antigens. For example, polyclonal and monoclonal antibodies 10 can be produced by methods well known in the art, as described, for example, in Harlow and Lane, Antibodies: A Laboratory Manual (Cold Spring Harbor Laboratory (1988)), which is incorporated herein by reference. Invention polypeptides can be used as immunogens in generating such 15 antibodies. Alternatively, synthetic peptides can be prepared (using commercially available synthesizers) and used as immunogens. Amino acid sequences can be analyzed by methods well known in the art to determine whether they encode hydrophobic or hydrophilic domains of the corresponding polypeptide. Altered antibodies such as 20 chimeric, humanized, CDR-grafted or bifunctional antibodies can also be produced by methods well known in the art. Such antibodies can also be produced by hybridoma, chemical synthesis or recombinant methods described, for example, in 25 Sambrook et al., supra., and Harlow and Lane, supra. Both anti-peptide and anti-fusion protein antibodies can be used. (see, for example, Bahouth et al., Trends Pharmacol. Sci. 12:338 (1991); Ausubel et al., Current Protocols in Molecular Biology (Supplement 47), John Wiley & Sons, New 30 York (1999), which are incorporated herein by reference).

The invention provides isolated anti-DD, anti-DED, or anti-NB-ARC antibodies having specific reactivity with a polypeptide of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 53, 56, or 58. In addition, isolated anti-DD, anti-DED, or anti-NB-ARC 5 antibodies are provided having specific reactivity with a polypeptide of SEQ ID NOS: 18 or 22. Furthermore, isolated anti-DD, anti-DED, or anti-NB-ARC antibodies are provided having specific reactivity with amino acids or peptides 10 within the polypeptides of SEQ ID NOS: 16, 20, and 26 that differ from SEQ ID NOS: 24 and 28. Invention polypeptides, or fragments thereof, and synthetic peptides can be used as 15 immunogens in generating the antibodies provided herein.

Antibody so produced can be used, *inter alia*, in diagnostic methods and systems to detect the level of DD, 15 DED or NB-ARC polypeptides present in a mammalian, preferably human, body sample, such as tissue or vascular fluid. Such antibodies can also be used for the immunoaffinity or affinity chromatography purification of 20 the invention DD, DED or NB-ARC domain. In addition, methods are contemplated herein for detecting the presence of an invention DD, DED or NB-ARC domain either within a cell, or on the surface of a cell, comprising contacting the 25 cell with an antibody that specifically binds to DD, DED or NB-ARC domain polypeptides, under conditions permitting binding of the antibody to the DD, DED or NB-ARC domain polypeptides, detecting the presence of the antibody bound to the DD, DED or NB-ARC domain polypeptide, and thereby detecting the presence of invention polypeptides on the 30 surface of the cell. With respect to the detection of such polypeptides, the antibodies can be used for *in vitro* diagnostic or *in vivo* imaging methods.

Immunological procedures useful for *in vitro* detection of target DD, DED or NB-ARC domain polypeptides in a sample include immunoassays that employ a detectable antibody. Such immunoassays include, for example, ELISA,  
5 Pandex microfluorimetric assay, agglutination assays, flow cytometry, serum diagnostic assays and immunohistochemical staining procedures which are well known in the art. An antibody can be made detectable by various means well known in the art. For example, a detectable marker can be  
10 directly or indirectly attached to the antibody. Useful markers include, for example, radionucleotides, enzymes, fluorogens, chromogens and chemiluminescent labels.

Invention anti-DD, anti-DED or anti-NB-ARC domain antibodies are contemplated for use herein to modulate the  
15 activity of the DD, DED or NB-ARC domain polypeptide in living animals, in humans, or in biological tissues or fluids isolated therefrom. The term "modulate" refers to a compound's ability to increase (e.g., via an agonist), decrease (e.g., via an antagonist), or otherwise modify  
20 (e.g., increasing a first DD, DED or NB-ARC domain activity while decreasing a second DD, DED or NB-ARC domain activity) the biological activity of an invention DD, DED or NB-ARC domain protein, such as binding to FADD, caspases such as caspase-8, DR4, DR5, Traf6, hToll, MyD88 and Fas, NF- $\kappa$ B or  
25 JNK modulating activity, or caspase such as caspase-8 modulating activity, apoptosis modulating activity, cell proliferation modulating activity, cell adhesion modulating activity, cell stress responses modulating activity, microbial infection response modulating activity, or B cell  
30 immunoglobulin class switching modulating activity, and the like. Accordingly, compositions comprising a carrier and an

amount of an antibody having specificity for DD, DED or NB-ARC domain polypeptides effective to block naturally occurring ligands or other DD-, DED- or NB-ARC domain-associated proteins, and the like, from binding to invention 5 DD, DED or NB-ARC domain polypeptides are contemplated herein. For example, a monoclonal antibody directed to an epitope of an invention DD, DED or NB-ARC domain polypeptide including an amino acid sequence set forth in SEQ ID NOS:2, 4, 6, 8, 10, 12, 53, 56 or 58, or SEQ ID NOS:16, 18, 20, 22 10 or 26, can be useful for this purpose.

The present invention further provides transgenic non-human mammals that are capable of expressing exogenous nucleic acids encoding DDs, DEDs or NB-ARC domains. As employed herein, the phrase "exogenous nucleic acid" refers 15 to nucleic acid sequence which is not native to the host, or which is present in the host in other than its native environment (e.g., as part of a genetically engineered DNA construct). In addition to naturally occurring levels of DD-, DED- or NB-ARC domain-containing proteins, invention 20 DDs, DEDs or NB-ARC domain can either be overexpressed or underexpressed (such as in the well-known knock-out transgenics) in transgenic mammals.

Also provided are transgenic non-human mammals capable of expressing nucleic acids encoding DD, DED or NB- 25 ARC domain polypeptides so mutated as to be incapable of normal activity, i.e., do not express native DD, DED or NB-ARC domain polypeptides. The present invention also provides transgenic non-human mammals having a genome comprising antisense nucleic acids complementary to nucleic 30 acids encoding DD, DED or NB-ARC domain polypeptides, placed

so as to be transcribed into antisense mRNA complementary to mRNA encoding DD, DED or NB-ARC domain polypeptides, which hybridizes to the mRNA and, thereby, reduces the translation thereof. The nucleic acid can additionally comprise an  
5 inducible promoter and/or tissue specific regulatory elements, so that expression can be induced, or restricted to specific cell types. Examples of nucleic acids are DNA or cDNA having a coding sequence the same or substantially the same as the coding sequence of SEQ ID NOS:13, 15, 17,  
10 19, 21 or 54, and preferably 1, 3, 5, 7, 9, 11 or 52. An example of a non-human transgenic mammal is a transgenic mouse. Examples of tissue specificity-determining elements are the metallothionein promoter and the L7 promoter.

Animal model systems which elucidate the  
15 physiological and behavioral roles of DD, DED or NB-ARC domain polypeptides are also provided, and are produced by creating transgenic animals in which the expression of the DD, DED or NB-ARC domain polypeptide is altered using a variety of techniques. Examples of such techniques include  
20 the insertion of normal or mutant versions of nucleic acids encoding a DD, DED or NB-ARC domain polypeptide by microinjection, retroviral infection or other means well known to those skilled in the art, into appropriate fertilized embryos to produce a transgenic animal. (See,  
25 for example, Hogan et al., Manipulating the Mouse Embryo: A Laboratory Manual (Cold Spring Harbor Laboratory, (1986)).

Also contemplated herein, is the use of homologous recombination of mutant or normal versions of DD, DED or NB-ARC domain genes with the native gene locus in transgenic  
30 animals, to alter the regulation of expression or the

structure of DD, DED or NB-ARC domain polypeptides (see, Capecchi et al., Science 244:1288 (1989); Zimmer et al., Nature 338:150 (1989); which are incorporated herein by reference). Homologous recombination techniques are well known in the art. Homologous recombination replaces the native (endogenous) gene with a recombinant or mutated gene to produce an animal that cannot express native (endogenous) protein but can express, for example, a mutated protein which results in altered expression of DD, DED or NB-ARC domain polypeptides.

In contrast to homologous recombination, microinjection adds genes to the host genome, without removing host genes. Microinjection can produce a transgenic animal that is capable of expressing both endogenous and exogenous DDs, DEDs or NB-ARC domains. Inducible promoters can be linked to the coding region of nucleic acids to provide a means to regulate expression of the transgene. Tissue specific regulatory elements can be linked to the coding region to permit tissue-specific expression of the transgene. Transgenic animal model systems are useful for *in vivo* screening of compounds for identification of specific ligands, i.e., agonists and antagonists, which activate or inhibit protein responses.

Invention nucleic acids, oligonucleotides (including antisense), vectors containing same, transformed host cells, polypeptides and combinations thereof, as well as antibodies of the present invention, can be used to screen compounds *in vitro* to determine whether a compound functions as a potential agonist or antagonist to invention DDs, DEDs or NB-ARC domains. These *in vitro* screening

assays provide information regarding the function and activity of invention DDs, DEDs, or NB-ARC domains which can lead to the identification and design of compounds that are capable of specific interaction with one or more types of 5 polypeptides, peptides or proteins.

By the known homology of invention DDs, DEDs and NB-ARC domains to known proteins containing these domains, it is within the scope of the invention that invention DD, DED or NB-ARC domain also have a role in cellular pathways 10 that effect apoptosis, cell proliferation, cell adhesion, cell stress responses, responses to microbial infection, and B cell immunoglobulin class switching. Thus, invention DDs, DEDs or NB-ARC domains also provide drug discovery targets for a broad variety of pathologies including 15 infection, autoimmunity, inflammation, allergy, allograft-rejection and sepsis, and for a broad variety of cancer pathologies, such as, gliomas, carcinomas, sarcomas, melanomas, hamartomas and the like. In certain aspects of the invention, invention DD, DED or NB-ARC domain proteins, 20 agonist or antagonists thereto, are used to treat infection, autoimmunity, inflammation, allergy, allograft-rejection, sepsis, keratinocyte hyperplasia, neoplasia, keloid, benign prostatic hypertrophy, inflammatory hyperplasia, fibrosis, smooth muscle cell proliferation in arteries following 25 balloon angioplasty (restenosis), and the like. Exemplary cancer pathologies contemplated herein for treatment include, gliomas, carcinomas, adenocarcinomas, sarcomas, melanomas, hamartomas, leukemias, lymphomas, and the like. Exemplary infections contemplated herein for treatment 30 include bacterial infections such as infections caused by *Chlamydia* (Ojcius et al., J. Immunol. 161:4220-6 (1998)),

*Pseudomonas* (Hauser and Engel, Infect. Immun. 67: 5530-7 (1999)), *Salmonella* (Hersh et al., Proc. Natl. Acad. Sci. USA, 96:2396-401 (1999)), *Shigella* (Zychlinsky, et al., Nature 358:167-9 (1992)), and *Mycobacterium* (Oddo, et al., 5 J. Immunol. 160:5448-54 (1998)), which are incorporated herein by reference.

Chlamydia trachomatis is a eubacterial pathogen accounting for the major cause of blindness in Asia and Africa and is the most common sexually transmitted disease 10 in the United States. Chlamydia infections have been linked to pelvic inflammatory disease, urethritis, and infertility. Different strains of Chlamydia have also been linked to arthritis, pneumonia, upper respiratory and ear infections, asthma, vasculitis, atherosclerosis, and other vascular 15 diseases. In addition, chronic Chlamydia infections have also been linked to cancer. A recent longitudinal study provided evidence that patients infected with *Chlamydia trachomatis* serotype G carry a 6.6-fold increased risk of developing cervical cancer.

20 Also provided herein are methods of treating pathologies, said method comprising administering an effective amount of an invention therapeutic composition. Such compositions are typically administered in a physiologically compatible composition.

25 Methods of treating pathologies of abnormal cell proliferation include methods of modulating the activity of one or more oncogenic proteins, wherein the oncogenic proteins specifically interact with a DD, DED or NB-ARC domain. Methods of modulating the activity of such

100-021-054-100-000

oncogenic proteins include contacting the oncogenic protein with a substantially pure DD, DED or NB-ARC domain or an active fragment (i.e., oncogenic protein-binding fragment) thereof. This contacting can modulate the activity of the 5 oncogenic protein, thereby providing a method of treating a pathology caused by the oncogenic protein. Further methods of modulating the activity of oncogenic proteins include contacting the oncogenic protein with an agent, wherein the agent modulates the interactions between the DD, DED or NB- 10 ARC domain and the oncogenic protein.

Methods of treating bacterial infections include methods of modulating the activity of one or more bacterial proteins that contain or specifically interact with a DD, DED or NB-ARC domain. Methods of modulating the activity of 15 such a bacterial protein include contacting the bacterial protein with a substantially pure DD, DED or NB-ARC domain or an active fragment thereof. This contacting can modulate the activity of the bacterial protein, thereby providing a method of treating a pathology caused by the bacteria. 20 Further methods of modulating the activity of bacterial proteins include contacting the bacterial protein with an agent, including, for example, a nucleic acid, a drug, a peptide, or a protein, including a secreted protein or an antibody, wherein the agent modulates a DD, DED or NB-ARC 25 domain of a bacterial protein or the agent modulates the interactions between a DD, DED or NB-ARC domain and a bacterial protein.

Methods of treating bacterial infections can further include methods of modulating the activity of one or 30 more host cell proteins that specifically interact with a

bacterial protein that contains or specifically interacts with a DD, DED or NB-ARC domain. Methods of modulating the activity of such a host cell protein include contacting the host cell protein with a substantially pure DD, DED or NB-  
5 ARC domain or an active fragment thereof. This contacting can modulate the activity of the host cell protein, thereby providing a method of treating a pathology caused by the interaction of the host cell and bacterial proteins.  
Further methods of modulating the activity of host cell  
10 proteins include contacting the host cell protein with an agent, wherein the agent modulates the interactions between a host cell protein and a bacterial protein that contains or specifically interacts with a DD, DED or NB-ARC domain. All of the above methods for treating bacterial infections can  
15 be used alone or in combination with other methods of treating bacterial infections.

Methods of treating immune-based pathologies such as infection, autoimmunity, inflammation, allergy, allograft-rejection, and sepsis will include modulating the  
20 activity of one or more proteins that modulate immune response, wherein the protein that modulates immune response specifically interact with a DD, DED or NB-ARC domain.  
Methods of modulating the activity of such protein that modulates immune response will include contacting the  
25 protein that modulates immune response with a substantially pure DD, DED or NB-ARC domain or an active fragment (i.e., protein-binding fragment) thereof. This contacting will modulate the activity of the protein that modulates immune response, thereby providing a method of treating a pathology  
30 caused by the protein that modulates immune response.  
Further methods of modulating the activity of a protein that

modulates immune response will include contacting the protein that modulates immune response with an agent, wherein the agent modulates the interactions between the DD, DED or NB-ARC domain and the protein that modulates immune response.

Also contemplated herein, are therapeutic methods using invention pharmaceutical compositions for the treatment of pathological disorders in which there is too little cell division, such as, for example, bone marrow aplasias, immunodeficiencies due to a decreased number of lymphocytes, and the like. Methods of treating a variety of inflammatory diseases with invention therapeutic compositions are also contemplated herein, such as treatment of sepsis, fibrosis (e.g., scarring), arthritis, graft versus host disease, and the like. Therapeutic methods using invention polypeptides or nucleic acids are also contemplated for treating infectious diseases.

The present invention also provides therapeutic compositions useful for practicing the therapeutic methods described herein. Therapeutic compositions of the present invention, such as pharmaceutical compositions, contain a physiologically compatible carrier together with an invention DD, DED or NB-ARC domain (or functional fragment thereof), a DD, DED or NB-ARC domain modulating agent, such as a compound (agonist or antagonist) identified by the methods described herein, or an anti-DD, anti-DED or anti-NB-ARC domain antibody, as described herein, dissolved or dispersed therein as an active ingredient. In a preferred embodiment, the therapeutic composition is not immunogenic

when administered to a mammal or human patient for therapeutic purposes.

As used herein, the terms "pharmaceutically acceptable", "physiologically compatible" and grammatical variations thereof, as they refer to compositions, carriers, diluents and reagents, are used interchangeably and represent that the materials are capable of administration to a mammal without the production of undesirable physiological effects such as nausea, dizziness, gastric upset, and the like.

The preparation of a pharmacological composition that contains active ingredients dissolved or dispersed therein is well known in the art. Typically such compositions are prepared as injectables either as liquid solutions or suspensions; however, solid forms suitable for solution, or suspension, in liquid prior to use can also be prepared. The preparation can also be emulsified.

The active ingredient can be mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient in amounts suitable for use in the therapeutic methods described herein. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like, as well as combinations of any two or more thereof. In addition, if desired, the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and the like, which enhance the effectiveness of the active ingredient.

The therapeutic composition of the present invention can include pharmaceutically acceptable salts of the components therein. Pharmaceutically acceptable nontoxic salts include the acid addition salts (formed with 5 the free amino groups of the polypeptide) that are formed with inorganic acids such as, for example, hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, phosphoric acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, 10 oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, anthranilic acid, cinnamic acid, naphthalene sulfonic acid, sulfanilic acid, and the like.

Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, 15 sodium hydroxide, ammonium hydroxide, potassium hydroxide, and the like; and organic bases such as mono-, di-, and tri-alkyl and -aryl amines (e.g., triethylamine, diisopropyl amine, methyl amine, dimethyl amine, and the like) and optionally substituted ethanolamines (e.g., ethanolamine, 20 diethanolamine, and the like).

Physiologically tolerable carriers are well known in the art. Exemplary liquid carriers are sterile aqueous solutions that contain no materials in addition to the active ingredients and water, or contain a buffer such as 25 sodium phosphate at physiological pH, physiological saline or both, such as phosphate-buffered saline. Still further, aqueous carriers can contain more than one buffer salt, as well as salts such as sodium and potassium chlorides, dextrose, polyethylene glycol and other solutes.

Liquid compositions can also contain liquid phases in addition to and to the exclusion of water. Exemplary additional liquid phases include glycerin, vegetable oils such as cottonseed oil, and water-oil emulsions.

5 As described herein, an "effective amount" is a predetermined amount calculated to achieve the desired therapeutic effect, e.g., to modulate activity of an invention DD, DED or NB-ARC domain. The required dosage will vary with the particular treatment and with the  
10 duration of desired treatment; however, it is anticipated that dosages between about 10 micrograms and about 1 milligram per kilogram of body weight per day will be used for therapeutic treatment. It may be particularly advantageous to administer such compounds in depot or  
15 long-lasting form as discussed hereinafter. A therapeutically effective amount is typically an amount of an DD-, DED- or NB-ARC domain-modulating agent or compound identified herein that, when administered in a physiologically acceptable composition, is sufficient to  
20 achieve a plasma concentration of from about 0.1  $\mu\text{g}/\text{ml}$  to about 100  $\mu\text{g}/\text{ml}$ , preferably from about 1.0  $\mu\text{g}/\text{ml}$  to about 50  $\mu\text{g}/\text{ml}$ , more preferably at least about 2  $\mu\text{g}/\text{ml}$  and usually 5 to 10  $\mu\text{g}/\text{ml}$ . Therapeutic invention anti-DD,  
25 anti-DED or anti-NB-ARC domain antibodies can be administered in proportionately appropriate amounts in accordance with known practices in this art.

In accordance with still another embodiment of the present invention, there are provided methods for identifying compounds which bind to DD, DED or NB-ARC domain

polypeptides. The invention proteins may be employed in a competitive binding assay. Such an assay can accommodate the rapid screening of a large number of compounds to determine which compounds, if any, are capable of binding to DDs, DEDs or NB-ARC domains. Subsequently, more detailed assays can be carried out with those compounds found to bind, to further determine whether such compounds act as modulators, agonists or antagonists of invention DDs, DEDs or NB-ARC domains. Compounds that bind to and/or modulate invention DDs, DEDs or NB-ARC domains can be used to treat a variety of pathologies mediated by invention DDs, DEDs or NB-ARC domains.

In another embodiment of the invention, there is provided a bioassay for identifying compounds which modulate the activity of invention DD, DED or NB-ARC domain polypeptides. Invention DD, DED or NB-ARC domain polypeptides are known to influence the activities of, for example, NF- $\kappa$ B, JNK, and caspase-8. Thus a reporter gene construct to assay for NF- $\kappa$ B activity can be used to test invention DED activity (see Examples). According to this method, invention DD, DED or NB-ARC domain polypeptides are contacted with an "unknown" or test substance, the activity of the invention DD, DED or NB-ARC domain polypeptide is monitored subsequent to the contact with the "unknown" or test substance, and those substances which effect a resultant modulation of, for example, NF- $\kappa$ B or JNK activity or caspase, such as caspase-8, activity are identified as functional ligands for DD, DED or NB-ARC domain polypeptides.

Alternative bioassays for identifying compounds which modulate the activity of invention DD, DED or NB-ARC domain polypeptides can be used which routinely are used to test for protein:protein interactions. Such bioassays 5 include yeast two-hybrid assays, glutathione-S-transferase fusion protein binding assays, co-immunoprecipitation assays, and the like. Such assays are well known in the art and can be found in standard reference texts such as Sambrook et al., *supra*, and Ausubel et al., *supra*, 1999.

10 In accordance with another embodiment of the present invention, transformed host cells that recombinantly express invention polypeptides can be contacted with a test compound, and the modulating effect(s) thereof can then be evaluated by comparing the DD-, DED-, or NB-ARC domain- 15 mediated response (e.g., via reporter gene expression) in the presence and absence of test compound, or by comparing the response of test cells or control cells (i.e., cells that do not express DD, DED or NB-ARC domain polypeptides), to the presence of the compound.

20 As used herein, a compound or a signal that "modulates the activity" of invention DD, DED or NB-ARC domain polypeptides refers to a compound or a signal that alters the activity of DD, DED or NB-ARC domain polypeptides so that the activity of the invention polypeptide is 25 different in the presence of the compound or signal than in the absence of the compound or signal. In particular, such compounds or signals include agonists and antagonists. An agonist encompasses a compound or a signal that activates DD, DED or NB-ARC domain protein expression. Alternatively, 30 an antagonist includes a compound or signal that interferes

with DD, DED or NB-ARC domain expression. Typically, the effect of an antagonist is observed as a blocking of agonist-induced protein activation. Antagonists include competitive and non-competitive antagonists. A competitive 5 antagonist (or competitive blocker) interacts with or near the site specific for agonist binding. A non-competitive antagonist or blocker inactivates the function of the polypeptide by interacting with a site other than the agonist interaction site.

10 As understood by those of skill in the art, assay methods for identifying compounds that modulate DD, DED or NB-ARC domain activity generally require comparison to a control. One type of a "control" is a cell or culture that is treated substantially the same as the test cell or test 15 culture exposed to the compound, with the distinction that the "control" cell or culture is not exposed to the compound. For example, in methods that use voltage clamp electrophysiological procedures, the same cell can be tested in the presence or absence of compound, by merely changing 20 the external solution bathing the cell. Another type of "control" cell or culture may be a cell or culture that is identical to the transfected cells, with the exception that the "control" cell or culture do not express native proteins. Accordingly, the response of the transfected cell 25 to compound is compared to the response (or lack thereof) of the "control" cell or culture to the same compound under the same reaction conditions.



In yet another embodiment of the present invention, the activation of DD, DED or NB-ARC domain polypeptides can be modulated by contacting the polypeptides with an effective amount of at least one compound identified 5 by the above-described bioassays.

In accordance with another embodiment of the present invention, there are provided methods for identifying a binding agent that binds a DD, DED or NB-ARC domain, where a DD, DED, or NB-ARC domain from DAP3, IRAK4, 10 CTDD, DED4 or NIDD is contacted with a candidate binding agent and then the association of the domain and candidate binding agent are detected. An association between the candidate binding agent and the domain identifies the candidate binding agent as a binding agent that binds a DD, 15 DED, or NB-ARC domain from DAP3, IRAK4, CTDD, DED4 or NIDD. The association between the candidate binding agent and the domain can be detected using a variety of methods well known in the art, for example, co-immunoprecipitation assays and transcription based assays such as reporter assays and two- 20 hybrid assays. Such assays are well known in the art and can be found in standard reference texts such as Sambrook et al., *supra*, and Ausubel et al., *supra*, 1999. Additional methods include, for example, scintillation proximity assay (SPA) (Alouani, Methods Mol. Biol. 138:135-41 (2000)), UV or 25 chemical cross-linking (Fancy, Curr. Opin. Chem. Biol. 4:28-33 (2000)), competition binding assays (Yamamura et al., Methods in Neurotransmitter Receptor Analysis, Raven Press, New York, 1990), biomolecular interaction analysis (BIA) (Weinberger et al., Pharmacogenomics 1:395-416 (2000)), mass 30 spectrometry (MS) (McLafferty et al., Science 284:1289-1290 (1999) and Degterev, et al., Nature Cell Biology 3:173-182

(2001)), nuclear magnetic resonance (NMR) (Shuker et al., Science 274:1531-1534 (1996), Hajduk et al., J. Med. Chem. 42:2315-2317 (1999), and Chen and Shapiro, Anal. Chem. 71:669A-675A (1999)), and fluorescence polarization assays (FPA) (Degterev et al., *supra*, 2001) which are incorporated herein by reference. The identified binding agent can be, for example, another protein, including an antibody or fragment thereof, or a drug or other agent.

In accordance with another embodiment of the present invention, there are provided methods for identifying an effective agent that modulates the association of a DD, DED or NB-ARC domain from DAP3, IRAK4, CTDD, DED4 or NIDD with a protein that binds the DD, DED or NB-ARC domain where the proteins are contacted under conditions that allow the domain and a protein that binds the domain to associate with an agent suspected of being able to modulate the association of the domain and protein that binds the domain. Detection of a modulated association of the domain and protein that binds the domain identifies the agent as an effective agent. An altered association can be detected, for example, by measuring the activity of NF- $\kappa$ B or caspases or by using other methods well known in the art and described herein. The effective agent can be, for example, another protein, including an antibody, or a drug.

In accordance with another embodiment of the present invention, there are provided methods of modulating a cell process such as apoptosis, cell proliferation, cell adhesion, cell stress responses, responses to microbial infection, and B cell immunoglobulin class switching, by contacting a cell with an effective agent that modulates the

activity of a DD-, DED-, or NB-ARC domain. For example, a nucleic acid molecule encoding a DD, DED or NB-ARC domain from DAP3, IRAK4, CTDD, DED4 or NIDD, can be introduced into a cell and expression of the DD, DED or NB-ARC domain can modulate a cell process within the cell. In addition, an antisense nucleotide sequence that specifically hybridizes to a nucleic acid molecule encoding a DD, DED or NB-ARC domain from DAP3, IRAK4, CTDD, DED4 or NIDD, can be introduced into a cell where hybridization can reduce or inhibit the expression of the DD, DED or NB-ARC domain in the cell which modulates a cell process within the cell. Furthermore, a cell process can be modulated by contacting a cell with a DD, DED or NB-ARC domain or functional fragment thereof, an effective agent as described above, or an anti-DD, anti-DED or anti-NB-ARC domain antibody where the DD, DED, or NB-ARC domain is from DAP3, IRAK4, DED4 or NIDD.

Methods are also provided for modulating an activity mediated by a DD, DED or NB-ARC domain, by contacting the DD, DED or NB-ARC domain with an effective agent identified as described above. The modulated activity can be, for example, binding of a DD, DED or NB-ARC domain protein to a protein that binds a DD, DED or NB-ARC domain, NF- $\kappa$ B activity, caspase such as caspase-8 activity, apoptosis activity, cell proliferation activity, cell adhesion, cell stress response activity, responses to microbial infection activity, and B cell immunoglobulin class switching activity. For example, the activity of NF- $\kappa$ B or caspases can be modulated by a cell with an effective agent that modulates the activity of a DD-, DED-, or NB-ARC domain.

In accordance with another embodiment of the present invention, there are provided methods of diagnosing a pathology characterized by an increased or decreased level of a DD, DED or NB-ARC domain from DAP3, IRAK4, CTDD, DED4 5 or NIDD in a subject. For example, a test sample from a subject can be contacted with an agent that can bind the DD, DED or NB-ARC domain under suitable conditions, which allow specific binding of the agent to the DD, DED or NB-ARC domain, and then the amount of specific binding in the test 10 sample can be compared with the amount of specific binding in a control sample, where an increased or decreased amount of specific binding in said test sample as compared to a control sample is diagnostic of a pathology. The agent that can bind the DD, DED or NB-ARC domain can be, for example, 15 an anti-DD, anti-DED, or anti-NB-ARC domain antibody, FADD, caspases such as caspase-8 and caspase-10, DR4, DR5, Traf6, hToll, MyD88 Fas, Raidd, IRAK, IRAK-2, IRAK-M, p75NTR, Tradd, DAP kinase, RIP, NMP84, ankyrins, Flip, PEA15, Flash, BAP31, BAR, DEDT/DEDD, CTDD, or DAP3. In addition, a test 20 sample containing nucleic acid molecules from a subject can be contacted under high stringency hybridization conditions with an oligonucleotide specific for one of the above DD, DED, or NB-ARC domain containing proteins, and the amount of specific binding in the test sample can be compared with the 25 amount of specific binding in a control sample, where an increased or decreased amount of specific binding in the test sample as compared to said control sample is diagnostic of a pathology.

In accordance with another embodiment of the present invention, there are provided methods for diagnosing cancer, said method comprising detecting, in said subject, a defective sequence or mutant of SEQ ID NOS:1, 3, 5, 7, 9, 5 11, or 52.

In accordance with another embodiment of the present invention, there are provided methods for diagnosing a bacterial infection or monitoring the progression of a bacterial infection by detecting in a subject either nucleic acid molecules or proteins specific to a bacterial pathogen. For example, a *Chlamydia* infection can be detected by contacting a test sample from a subject with an antibody specifically reactive with a peptide or polypeptide consisting of any of SEQ ID NOS: 10, 20, 53, 56, or 58. In 15 addition, a test sample from a subject can be contacted under high stringency conditions with a nucleic acid molecule encoding any of SEQ ID NOS: 10, 20, 53, 56, or 58.

In accordance with another embodiment of the present invention, there are provided diagnostic systems, 20 preferably in kit form, comprising at least one invention nucleic acid in a suitable packaging material. The diagnostic nucleic acids are derived from the DD-, DED- or NB-ARC domain-encoding nucleic acids described herein. In one embodiment, for example, the diagnostic nucleic acids 25 are derived from any of SEQ ID NOS:1, 3, 5, 7, 9, 11 or 52. Invention diagnostic systems are useful for assaying for the presence or absence of nucleic acid encoding DD, DED or NB-ARC domain polypeptides in either genomic DNA or in transcribed nucleic acid (such as mRNA or cDNA) encoding DD, 30 DED or NB-ARC domain polypeptides.

A suitable diagnostic system includes at least one invention nucleic acid, preferably two or more invention nucleic acids, as a separately packaged chemical reagent(s) in an amount sufficient for at least one assay.

- 5 Instructions for use of the packaged reagent are also typically included. Those of skill in the art can readily incorporate invention nucleic probes and/or primers into kit form in combination with appropriate buffers and solutions for the practice of the invention methods as described  
10 herein.

As employed herein, the phrase "packaging material" refers to one or more physical structures used to house the contents of the kit, such as invention nucleic acid probes or primers, and the like. The packaging  
15 material is constructed by well known methods, preferably to provide a sterile, contaminant-free environment. The packaging material has a label which indicates that the invention nucleic acids can be used for detecting a particular sequence encoding DD, DED or NB-ARC domain  
20 polypeptides including the nucleotide sequences set forth in SEQ ID NOS:1, 3, 5, 7, 9, 11 or 52 or mutations or deletions therein, thereby diagnosing the presence of, or a predisposition for, cancer. In addition, the packaging material contains instructions indicating how the materials  
25 within the kit are employed both to detect a particular sequence and diagnose the presence of, or a predisposition for, cancer.

The packaging materials employed herein in relation to diagnostic systems are those customarily utilized in nucleic acid-based diagnostic systems. As used  
30

herein, the term "package" refers to a solid matrix or material such as glass, plastic, paper, foil, and the like, capable of holding within fixed limits an isolated nucleic acid, oligonucleotide, or primer of the present invention.

5 Thus, for example, a package can be a glass vial used to contain milligram quantities of a contemplated nucleic acid, oligonucleotide or primer, or it can be a microtiter plate well to which microgram quantities of a contemplated nucleic acid probe have been operatively affixed.

10 "Instructions for use" typically include a tangible expression describing the reagent concentration or at least one assay method parameter, such as the relative amounts of reagent and sample to be admixed, maintenance time periods for reagent/sample admixtures, temperature, 15 buffer conditions, and the like.

All U.S. patents and all publications mentioned herein are incorporated in their entirety by reference thereto. The invention will now be described in greater detail by reference to the following non-limiting examples.

20 **EXAMPLES**

**I. Binding Activity of DAP3**

FADD is an apoptosis-inducing adapter protein that uses its DD to bind the intracellular domain of Fas and its Death Effector Domain (DED) to bind corresponding DEDs in 25 the N-terminal prodomain of pro-Caspase-8 (pro-Casp8) (Boldin et al., Cell 85:803-815 (1996); Muzio et al., Cell 85:817-827 (1996)). During two-hybrid screens of cDNA

libraries using FADD as a bait, interactions were detected with DAP3, a protein previously implicated in death receptor-mediated apoptosis through unknown mechanisms (Kissil et al., EMBO J. 18:353-362 (1999)). The DAP3 5 protein contains a putative nucleotide-binding motif (P-loop) but has not been previously reported to contain other recognizable domains. The DAP3 nucleotide sequence is found at GenBank accession No. X83544 and is referenced herein as SEQ ID NO:13, the amino acid sequence (GI 4758118) 10 is referenced as SEQ ID NO:14.

To test DAP3 binding, various DNA constructs were made. Wild-type and mutant cDNAs encoding full-length or fragments of human DAP3, FADD, or pro-Casp8 were engineered using PCR from the plasmids pcDNA3-hDAP3, pcDNA3-DAP3K134A, 15 pcDNA3-Flag-FADD, pcDNA3-Flag-Mch5, pcDNA3-Flag-Mch5 (cys/ala) (Kissil et al., J. Biol. Chem. 270:27932-27936 (1995); Kissil et al., EMBO J. 18:353-362 (1999); Boldin et al., Cell 85:803-815 (1996); Muzio et al., Cell 85:817-827 (1996); Torii et al., EMBO J. 18:6037-6049 (1999)) and 20 cloned into the EcoRI and XhoI sites of: (a) yeast two-hybrid vectors, pGilda and pJG4-5, which produce fusion proteins with a LexA DNA-binding domain or a B42 transactivation domain, respectively, at the N-terminus under the control of a *GAL1* promoter (Estojak et al., Mol. 25 Cell Biol. 15:5820 (1995)); (b) pcDNA3-Flag or pcDNA3-HA for mammalian expression (Takayama et al., EMBO J. 16:4887 (1997)); (c) pET21d-N-His<sub>6</sub> for bacterial expression; or (d) p426 for expression in yeast. The cDNAs encoding DR4, DR4 (DDD), and wild-type DR5 were generated by PCR from

pCR3.V64- Met-Flag-Trail-R1 and pCR3.V64-Met-Flag-Trail-R2 (Schneider, et al., FEBS Lett. 416:329 (1997)) and cloned into EcoRI and XhoI sites of pcDNA3 (Invitrogen; Carlsbad CA).

5 Two-hybrid comparisons of DAP3 interactions with numerous other proteins was used to confirm the specificity of binding results with DAP3 (Table 1). For two-hybrid cDNA library screening and protein interaction assays, library screening by the yeast two-hybrid method was performed as  
10 described (Sato et al., Science 268:411 (1995); Matsuzawa et al., EMBO J. 17:2736 (1998)) using the pGilda plasmid encoding human FADD as a bait, a human Jurkat T-cell cDNA library (gift from Brian Seed (Massachusetts General Hospital, Harvard University) and the EGY48 strain  
15 *Saccharomyces cerevisiae* (MAT, trp1, ura3, his, leu2::plexApo6-leu2) (Estojak et al., Mol. Cell Biol. 15:5820 (1995)). Cells were grown in either YPD medium with 1% yeast extract, 2% polypeptone and 2% glucose, or in Burkholder's minimal medium (BMM) fortified with appropriate  
20 amino acids. Transformations were performed by a LiCl method using 0.1 mg of pJG4-5 cDNA library DNA and 5 mg denatured salmon sperm DNA. Clones that formed on Leu-deficient BMM plates containing 2% galactose or 1% raffinose were transferred to BMM plates containing leucine and  
25 2% glucose, and filter assays were performed for β-galactosidase measurements as described (Sato et al., Proc Natl. Acad. Sci. USA 91:9238 (1994)). From an initial screen of ~2 x 10<sup>7</sup> transformants, 380 clones were identified which transactivated the *LEU2* reporter gene based on ability  
30 to grow on leucine-deficient media after 4 days. Of those, 20 colonies were also positive for β-galactosidase, as

tested by filter assays where color was scored after 1 hr. Two of these clones encoded DAP3 and two encoded FADD.

For most 2-hybrid assays, yeast strain EGY48 was transformed with yeast expression plasmids encoding various 5 proteins expressed as fusions with either a N-terminal LexA DNA-binding domain encoded by pGilda plasmid or B42 transactivation domain encoded by pJG4-5 plasmid. Transformants were scored for activation of *LEU2* and *lacZ* reporter genes under the control of LexA operators (Estojak 10 et al., *Mol. Cell Biol.* 15:5820 (1995)). Plasmid combinations that resulted in growth on leucine-deficient media within 4 days were considered positive.  $\beta$ -galactosidase activity of each colony was also tested by filter assay, scoring color (blue/white) after 1 hr. For 15 three-hybrid assays, in addition to pGilda and pJG4-5 plasmids, p426 plasmid was used for the expression of DAP3. Plasmid combinations that resulted in growth on leucine-deficient media within 10 days were considered positive.

Table 1 shows DAP3 interacts with FADD, caspase-8, 20 DR4, and DR5 in yeast two-hybrid assays. Yeast strain EGY48 was transformed with yeast expression plasmids encoding various proteins expressed as fusions with either an N-terminal LexA DNA-binding domain or B42 transactivation domain. Transformants were scored for activation of *LEU2* 25 and *lacZ* reporter genes under the control of LexA operators. Plasmid combinations that resulted in growth on leucine-deficient media within 4 days were scored as positive (+).  $\beta$ -galactosidase activity of each colony was also tested by filter assay and scored as blue (+) or white (-) after 60

min. Agreement between both methods of assay was obtained in all cases.

Table 1. DAP3 Interactions in Yeast Two-hybrid Assays

	<b>DBD</b>	<b>TA</b>	<b>Leu</b>	<b>β-Gal</b>
5	FADD	DAP3	+	+
	FADD	Empty	-	-
	Empty	DAP3	-	-
10	Casp 8	FADD	+	+
	Casp 8	Fas	-	-
	Casp 8	DAP3	+	+
	Casp8 PRO	DAP3	+	+
	Casp8 CAT	DAP3	-	-
15	Casp9 CARD	DAP3	-	-
	Empty	Casp 8	-	-
	FADD	Casp 8	+	+
	DAP3	Casp 8	+	+
	DAP3	Empty	-	-
	Fas	FADD	+	+
	Fas	DAP3	-	-
20	DR4	FADD	-	-
	DR4	DAP3	+	+
	DR5	FADD	-	-
	DR5	DAP3	+	+

DAP3 binding activity, association with FADD, and  
25 regulation of FADD-induced apoptosis was tested (Figure 1). For co-immunoprecipitation assays, HEK293T or HEK293-EBNA cells ( $2 \times 10^6$ ) in 10 cm plates were transiently transfected

with 10 µg of each protein-encoding plasmids (20 µg total DNA) using 50 µl of Superfect™ (QIAGEN; Valencia CA) and harvested 1 day later. Alternatively, 2-5 × 10<sup>8</sup> untransfected Jurkat or HT1080 cells were used without transfection. Cells were suspended in 0.5 ml lysis buffer containing 0.1% NP-40, 20 mM Tris-HCl, pH 7.5, 2 mM MgCl<sub>2</sub>, 1 mM EGTA, 130 mM NaCl (500 mM in the case of caspase-8) and protein inhibitors (Boehringer Mannheim/Roche Molecular Biochemicals; Indianapolis IN). In some cases, 0.1 mM ATP, ATPγS, GTP, or GTPγS was added to lysates. After pre-clearing with normal mouse or rabbit IgG and 25 µl Protein A- or protein G-agarose, immunoprecipitations (IPs) were performed using 25 µl of anti-FLAG antibody M2-conjugated agarose (Sigma; St. Louis MO), or using anti-HA antibody 12CA5 (Boehringer Mannheim), anti-DAP3 (BD Biosciences - Transduction Labs; Lexington KY), anti-DR4 (Santa Cruz Biotechnology; Santa Cruz CA), or anti-Fas (ALEXIS Biochemicals; San Diego CA) in combination with Protein A- or G-SEPHAROSE (25 µl) at 4°C for 4 hrs. Controls included IPs performed with an equivalent amount of normal mouse or rabbit IgG or unconjugated agarose. After extensive washing with lysis buffer, immune-complexes were fractionated by SDS-PAGE and transferred to nitrocellulose for immunoblotting using various antibodies, followed by incubation with HRPase-conjugated antibodies and detection using an enhanced chemiluminescence (ECL) system (Amersham Pharmacia Biotech Inc.; Piscataway NJ).

Figure 1A shows that endogenous DAP3 associates with endogenous FADD. Lysates from untransfected Jurkat and HT1080 cells were subjected to immunoprecipitation (IP) using either anti-DAP3 or control mouse IgG. Immune-

complexes were analyzed by SDS-PAGE and immunoblotting using anti-FADD (Figure 1A, top panel) and anti-DAP3 (Figure 1A, lower panel) antibodies. Figure 1B shows that DAP3 association with FADD is Fas-inducible. HEK293T cells were 5 transfected with plasmids encoding DAP3-Flag, FADD-HA, or both. After 1 day, cells were cultured without (-) or with (+) 100 ng/ml anti-Fas antibody CH11 and then lysed after 15 minutes. IPs were performed on cell lysates using anti-Flag, followed by immunoblotting using anti-HA (Figure 10 1B, top panel). The lysates (30 µl) were also analyzed directly without IP by SDS-PAGE and immunoblotting using anti-Flag and anti-HA antibodies (Figure 1B, lower panels).

Figure 1C shows DAP3 binds the DED of FADD. 293T cells were transfected with plasmids encoding DAP3-Flag 15 together with empty plasmid (CNTL), or plasmids encoding HA-tagged full-length FADD, FADD(DD) (residues 81-208), or FADD(DED) (residues 1-80). Lysates were prepared 1 day later and equivalent aliquots were subjected to IP using either anti-HA or anti-Flag antibody, followed by immunoblot 20 analysis using anti-Flag or anti-HA as indicated. Figure 1D shows mapping of FADD-binding region in DAP3. 293T cells were transfected with plasmids encoding FADD-HA and either empty plasmid (CNTL) or plasmids encoding Flag-tagged full-length DAP3, DAP3(ΔC) (residues 1-230) or DAP3(ΔN) 25 (residues 231-398) (Figure 1D, lower panel). IPs and subsequent immunoblot analysis of immune-complexes were then performed using anti-HA and anti-Flag antibodies, as described above.

Figure 1E shows that DAP3 modulates Fas-mediated generation of caspase-8-like protease activity. 293T cells were transfected with empty (-) or Fas-encoding (+) plasmids, together with empty plasmid (-) or plasmids 5 encoding full-length wild-type (WT) DAP3, DAP3(K134A), DAP3(ΔN), or DAP3(ΔC). After 1 day, lysates were assayed for protease activity using the caspase-8 substrate Ac-IETD-AFC, expressing data as relative fluorescence units (RFU) after normalization for total protein concentration. Figure 10 1F shows that DAP3 regulates Fas- and FADD-induced apoptosis. 293-EBNA cells were transfected with empty plasmid (CNTL) or plasmids encoding Fas, FADD, or pro-Casp8, in combination with empty plasmid (CNTL) or plasmids 15 encoding full-length DAP3, DAP3(K134A), DAP3(ΔN), or DAP3(ΔC). The percentage ( $\pm$  S.D.) of dead cells was determined 1 day later by trypan blue dye exclusion. Apoptosis was also confirmed by UV-microscopic examination of DAPI-stained fixed cells.

The endogenous FADD protein could be readily co-20 immunoprecipitated with endogenous DAP3 from cell lysates (Figure 1A) and, vice versa, endogenous DAP3 could be co-immunoprecipitated with endogenous FADD but not with several other proteins tested. The association of FADD with DAP3 was also markedly increased by stimulation of cells with 25 agonistic anti-Fas antibody CH11 (Figure 1B) but not by other types of unrelated apoptotic stimuli.

To map the domain in FADD responsible for binding DAP3, truncation mutants of FADD were engineered containing either the DD or DED with HA-epitope tags and co-expressed 30 with Flag-tagged DAP3 by transient transfection in HEK293T

cells. Based on co-immunoprecipitation assays, the DED of FADD was determined to interact with DAP3 (Figure 1C). The regions of DAP3 that interact with FADD were also tested using co-immunoprecipitation assays in experiments where 5 full-length DAP3 was compared with N-terminal or C-terminal truncation mutants of DAP3, expressed as Flag-tagged proteins. Full-length DAP3 and DAP3 lacking the N-terminal residues 1-230 (DAP3 $\Delta$ N) associated with FADD, whereas DAP3 lacking C-terminal residues 231-398 (DAP3 $\Delta$ C) did not 10 (Figure 1D). Thus, FADD binds the C-terminal domain of DAP3.

Since FADD is required for Fas-induced processing and activation of pro-Casp8 (Boldin et al., Cell 85:803-815 15 (1996)), the effects of expressing wild-type (WT) and mutant versions of DAP3 were tested on Fas-induced activation of caspases using the fluorogenic caspase-8 substrate Acetyl-Isoleucine-Glutamate-Threonine-Aspartyl-7-Amino-4-Trifluroromethyl-Coumarin (Ac-IETD-AFC) (Thornberry et al., J. Biol. Chem. 272:17907-17911 (1997)). Over-expression of 20 DAP3 did not significantly increase the amount caspase-8-like protease activity generated in cells in response to agonistic anti-Fas antibody (Figure 1E). In contrast, caspase-8-like activity was substantially reduced by over-expression of the DAP3 $\Delta$ N and DAP3 $\Delta$ C truncation mutants 25 or by DAP3(K134A), in which the P-loop motif was mutated. These protease activity results correlated with processing of pro-Casp8, as determined by immunoblotting. Furthermore, expression of these DAP3 mutants by transient transfection suppressed cell death induced by over-expression of Fas or 30 FADD but not by over-expression of pro-Casp8 (Figure 1F), suggesting that DAP3 functions downstream of Fas and FADD

but upstream of caspase-8. The DAP3 mutants however had no effect on cell death and apoptosis induced by unrelated cell death stimuli, such as staurosporine or anticancer drugs. Thus, consistent with its ability to bind FADD, DAP3 modulates apoptosis signaling through the Fas/FADD pathway at a proximal step, affecting activation of caspase-8.

## II. DAP3 Binds Prodomain of Pro-Casp8 and Regulates Caspase-8 Activation

During two-hybrid assays, evidence was obtained that DAP3 can bind pro-Casp8 as well as FADD (Table 1). Therefore, the effect of DAP3 on caspase-8 activation was further tested. For recombinant DAP3 production and bioactivity assay, pET21d-N-DAP3-His<sub>6</sub> was expressed in BL-21 cells (Stratagene Inc.; San Diego CA). Cells were grown in LB/ampicillin at 37°C to an O.D.<sub>600 nm</sub> of 0.5, then induced using 1 mM IPTG for 4 hrs before lysing by sonication in (50 mM NaH<sub>2</sub> PO<sub>4</sub>, pH8.0, 300 mM NaCl, 10 mM imidazole, 1 mg/ml lysozyme). DAP3-His<sub>6</sub> protein was affinity-purified using Ni-NTA spin-columns (QIAGEN Inc.; Valencia CA). pGEX4T-1 encoding GST, GST-Fas (residues 191-335), GST-TNFR2 (residues 266-439), GST-DR4 (residues 269-468) were expressed in XL-1-Blue cells (Stratagene) and affinity-purified using glutathione-SEPHAROSE 4B as described (Sato et al., FEBS Lett. 358:113 (1995)).

*In vitro* translated (IVT) pro-Casp8 and FADD proteins were produced using TNT-coupled reticulocyte lysates (Promega, Inc.; Madison WI) and pcDNA3-Flag-FADD or pcDNA3Flag-pro-Casp8. Negative controls were generated by IVT of empty pcDNA3. A total of 4 µl IVT mix was incubated

with 200 ng of purified DAP3-His<sub>6</sub> protein or TRAF3-His<sub>6</sub> (Leo, et al., *J. Biol. Chem.* 274:22414 (1999)) as a negative control in caspase buffer (50 mM HEPES, 100 mM NaCl, 1 mM EDTA, 0.1% CHAPS, 10% sucrose and 5 mM dithiothreitol (DTT)) in a total volume of 20 µl at 37°C for 30 min. In some cases, 0.1 mM ATP, ATPγS, GTP, or GTPγS was included. Caspase-8 activity was then measured by adding 10 µl of these reaction mixes to 89 µl of caspase buffer, followed by 1 µl of Ac-IETD-AFC (100 µM final concentration) (PharMingen Inc.; San Diego CA). Caspase activity was measured in cell lysates using Ac-IETD-AFC as a substrate, normalizing lysates for total protein concentration (Deveraux et al., *Nature* 388:300 (1997); Haraguchi et al., *J. Exp. Med.* 191:1709 (2000)). Caspase activity was measured at 37°C using a fluorometric plate reader (Perkin-Elmer, LS50B; Norwalk CT) in the kinetic mode with excitation and emission wave lengths of 405 and 510 nm, respectively, monitoring release of 7-amino-4-trifluoromethyl-coumarin (AFC) (RFU) from the substrate peptide after 30 min incubation.

Figure 2 shows DAP3 binding of prodomain of pro-Casp8 and regulates caspase-8 activation. 293T cells were transfected with plasmids encoding DAP3-Flag in combination with either empty plasmid (CNTL) or plasmids encoding HA-tagged full-length pro-Casp8, prodomain (PRO) (residues 1-215), or catalytic domain (CAT) (residues 212-496) (Figure 2A). Lysates were prepared 1 day later and equivalent aliquots subjected to IP and immunoblot analysis using anti-Flag and anti-HA antibodies, as indicated in Figure 2A. Asterisk denotes a non-specific band. Figure 2B shows that the proximal region of DAP3 associates with pro-Casp8. Co-

IP experiments were preformed, as described above, using 293T cells expressing HA-tagged pro-Casp8 in combination with Flag-tagged full-length DAP3, DAP3(ΔN), or DAP3(ΔC). Non-specific bands are denoted by asterisks.

5           Figure 2C shows that DAP3 binds GTP and stimulates activation of pro-Casp8 *in vitro* in a GTP-dependent manner. For nucleotide-binding assays, purified DAP3-His<sub>6</sub> protein (2 µg) was preincubated in 50 µl of 10 mM Tris-HCl, pH7.8, 100 mM NaCl, 1 mM DTT, 2 mM MnCl<sub>2</sub> and 5 mM ( $\alpha$ -<sup>32</sup>P)ATP or 5 mM ( $\alpha$ -<sup>32</sup>P)GTP with or without cold competitor (1 mM ATP or 1 mM GTP) at 4°C for 10 min and irradiated on ice using a UV-lamp (30W) at a distance of 5 cm for 10 min. The samples were passed through SEPHADEX G25 columns and analyzed by SDS-PAGE, autoradiography and immunoblotting using anti-DAP3  
10 antibody.  
15

In *vitro* translated pro-Casp8, FADD and bacteria-produced purified DAP3-His<sub>6</sub> were mixed in various combinations as indicated, and activity of caspase-8 was analyzed based on cleavage of Ac-IETD-AFC (RFU) (mean ± S.D; n = 3) (Figure 2C, left panel). TRAF3-His<sub>6</sub> served as a negative control (-) for DAP3-His<sub>6</sub>. DAP3-His<sub>6</sub> protein was incubated with <sup>32</sup>P-labeled ATP or GTP in the presence (+) or absence (-) of excess unlabeled nucleotides (Figure 2C, right top panel). Nucleotides were UV-crosslinked to DAP3 protein followed by analysis by SDS-PAGE and immunoblotting, where <sup>32</sup>P-bound nucleotides were detected by autoradiography and loading of equivalent amount of DAP3 was confirmed by incubation with anti-DAP3 antibody followed by ECL-detection.  
20  
25

Caspase-8 activation assays were performed using DAP3-His<sub>6</sub>, FADD, and pro-Casp8, as described above, in the presence of 0.1 mM ATP, ATPγS, GTP, or GTPγS (Figure 2C, right bottom panel). Data are expressed relative to 5 caspase-8 activity generated in the absence of added nucleotides (mean ± SD; n = 3).

Interaction of DAP3 with pro-Casp8 was confirmed by co-immunoprecipitation assays using transiently transfected HEK293T cells (Figure 2A). Furthermore, DAP3 was 10 determined to bind the N-terminal DED-containing prodomain of pro-Casp8 but not the catalytic domain of this protease (Table 1, Figure 2A). In contrast to the results obtained for FADD interactions with DAP3, analysis of DAP3 mutants indicated that the N-terminal domain (residues 1-230) of 15 DAP3 associates with pro-Casp8 (Figure 2B). Thus, while the C-terminal domain of DAP3 binds FADD, the N-terminal portion of DAP3 binds pro-Casp8.

To test the possibility that DAP3 enhances FADD-mediated activation of pro-Casp8, the effects of recombinant 20 purified DAP3 protein was tested on activation of *in vitro* translated pro-Casp8, measuring caspase-8 protease activity by cleavage of the fluorogenic peptide substrate Ac-IETD-AFC. Mixing FADD with pro-Casp8 resulted in a ~3-fold increase in caspase-8 activity (Figure 2C). Addition of 25 DAP3 to pro-Casp8 also increased protease activity by ~5-fold, indicating that DAP3 can trigger caspase-8 activation *in vitro*. Moreover, the co-addition of DAP3 and FADD resulted in a ~10-fold increase in caspase-8 activity, suggesting that the effects of FADD and DAP3 are at least 30 additive and possibly synergistic. Importantly, addition

of recombinant-purified DAP3 dominant-negative mutant proteins, DAP3 $\Delta$ N or DAP3 $\Delta$ C, inhibited FADD-induced activation of pro-Casp8 *in vitro* (Figure 2C). These data from an *in vitro* reconstitution system thus provide direct evidence that DAP3 can regulate FADD-mediated activation of pro-Casp8.

DAP3 contains a P-loop motif but has never been directly demonstrated to bind nucleotides. Using recombinant purified DAP3-His<sub>6</sub>, DAP3 protein was tested for binding *in vitro* to GTP or ATP, using a UV-crosslinking technique. DAP3-His<sub>6</sub> bound specifically to GTP but not ATP (Figure 2C). Moreover, GTP enhanced whereas GTP $\gamma$ S inhibited DAP3-mediated caspase-8 activation *in vitro* (Figure 2C). Thus, GTP binds and regulates the activity of DAP3.

### III. DAP3 Directly Binds Cytosolic Domain of DR4 and Modulates Trail Receptor-induced Apoptosis

The Trail receptors, DR4 and DR5, are known to recruit FADD and pro-Casp8 when bound by ligand, but FADD does not directly bind to the intracellular domains of these receptors (Schneider et al., Immunity 7:831-836 (1997); Walczak et al., EMBO J. 16:5386-5397 (1997); Kischkel et al., Immunity 12:611-620 (2000); Sprick et al., Immunity 12:599-609 (2000)), suggesting that another protein bridges FADD to DR4 and DR5. During two-hybrid analysis of DAP3 interactions, evidence was obtained that DAP3 binds the cytosolic domains of DR4 and DR5 (Table 1).

Figure 3 shows that DAP3 directly binds cytosolic domain of DR4 and modulates Trail Receptor-induced apoptosis. Figure 3A, left panel, shows that the death domain of DR4 is required for association with DAP3. 293T cells were transfected with plasmids encoding DAP3-Flag in combination with either empty plasmid (-) or plasmid encoding full-length DR4 or DR4 lacking the DD (residues 379-468). Co-IP and immunoblot experiments were performed as described above using anti-DR4 and anti-Flag antibodies.

Figure 3A, right panel, shows that endogenous DAP3 associates with DR4 in a ligand-dependent manner. Untransfected HT1080 cells were stimulated with 0.1 µg/ml TRAIL for various times, and lysates were prepared for immunoprecipitation using anti-DR4 or control (CNTL) antibody, followed by SDS-PAGE and immunoblot analysis using anti-DAP3 or anti-DR4 antibodies.

Figure 3B shows that purified recombinant DAP3 binds purified DR4 cytosolic domain. For *in vitro* protein interaction assays, purified DAP3-His<sub>6</sub> protein (+) or TRAF3-His<sub>6</sub> (-) (200 ng) were incubated with 1.0 µg of GST, GST-Fas (191-335), GST-DR4 (269-468), or GST-TNFR2 (266-439) immobilized on 10-20 µl of glutathione-beads in 0.1 ml of binding buffer (50 mM Tris-HCl, pH 7.5, 5mM MgCl<sub>2</sub>, 10% glycerol, 0.5 mg/ml BSA and 5 mM 2-mercaptoethanol) at 4°C for 60 min. The beads were washed 3-times with 1 ml binding buffer followed by boiling in 25 µl of SDS sample buffer. Eluted proteins were analyzed by SDS-PAGE (12% gel) followed by immunoblotting with anti-DAP3 and anti-GST antibodies. For Scatchard analysis, purified DAP3-His<sub>6</sub> protein at 0.1, 0.15, 0.25, 0.5 and 1 µM was incubated with 1.0 µg of GST-DR4 immobilized on 20 µl of glutathione-SEPHAROSE in 0.1 ml

of binding buffer at 4°C for 60 min. Free and DR4-bound DAP3 were separated by centrifugation of beads, and relative amounts of DAP3 in the supernatant and pellet fractions were determined by SDS-PAGE and immunoblotting using anti-DAP3 antibody (with ECL detection; Amersham). Analysis was performed using a scanning laser densitometry analysis of x-ray films (LKB densitometer; Amersham Pharmacia Biotech).

DAP3-His<sub>6</sub> protein was produced and purified from bacteria, then assayed for *in vitro* binding to purified cytosolic domains of Fas (lane 4), DR4 (lane 5) and TNFR2 (lane 6) expressed as GST-fusion proteins, or GST control protein (lane 3), immobilized on glutathione-SEPHAROSE (Figure 3B, left panel). DAP3-His<sub>6</sub> was loaded directly in the gel (lane 2) for assessing the proportion of input DAP3-His<sub>6</sub> recovered with immobilized GST-fusion proteins. Note that ~10-20% of input DAP3-His<sub>6</sub> bound GST-DR4. Lane 1 shows an equivalent amount of control His<sub>6</sub>-protein (TRAF3). His<sub>6</sub>-TRAF3 did not bind to GST-DR4, confirming the specificity of the results. Scatchard analysis of DAP3-His<sub>6</sub> binding to GST-DR4 cytosolic domain is shown in Figure 3B, right panel. For mapping of the region in DAP3 required for binding DR4, 293T cells were transfected and co-IP/immunoblot assays were preformed (Figure 3C).

Figure 3D shows that DAP3 mediates binding of DR4 and DR5 to FADD, as demonatrated by yeast 3-hybrid assay. Yeast cells were transformed with expression plasmids encoding various proteins expressed as fusions with either a N-terminal LexA DNA-binding domain (DBD) or B42

CONFIDENTIAL

transactivation domain (TA), with (+) or without (-) p426-DAP3 expression plasmid. Transformants were scored for activation of *LEU2* reporter gene, based on ability to grow when streaked on leucine-deficient medium.

5           Figure 3E shows that DAP3 association with FADD and pro-Casp8 is GTP-dependent. Nucleotide-dependence of interactions of DAP3 with FADD (top), pro-Casp8 (middle), and DR4 (bottom) were analyzed by adding 0.1 mM ATP, ATP $\gamma$ S, GTP, or GTP $\gamma$ S to lysates prior to performing co-  
10 immunoprecipitation assays. Figure 3F shows that DAP3 modulates apoptosis induction by Trail Receptors. 293-EBNA cells were transfected with either empty plasmid (CNTL) or plasmids encoding Fas, DR4 or DR5, in combination with either empty plasmid or plasmids encoding DAP3( $\Delta$ N),  
15 DAP3( $\Delta$ C), or the caspase-8 inhibitor, cowpox CrmA. Transfected cells were stimulated 1 day later with 0.1  $\mu$ g/ml agonistic anti-Fas antibody or 0.1  $\mu$ g/ml TRAIL. The percentage of dead cells was determined 16 hrs later by trypan blue dye exclusion (mean  $\pm$  S.D.; n = 3) (Varfolomeev  
20 et al., Immunity 9:267-276 (1998)).

Figure 3G shows that endogenous DAP3 is required for TRAIL-induced apoptosis. For antisense experiments, phosphodiester sense (5'-ATGATGCTGAAAGGAATA-3'; SEQ ID NO:40) and antisense oligonucleotides 1, 2 or 3 (see Figure 25 3G; SEQ ID NO:41) targeting DAP3 were synthesized and purified (Integrated DNA Technologies Inc.; Coralville IA). Oligonucleotides at 1.33  $\mu$ g/ml in TE buffer were mixed with 50  $\mu$ l LIPOFECTAMINE (Life Technolgies/Gibco; Rockville MD) in 2.5 ml OPTI-MEM medium, incubated at room temperature for 30 45 minutes, then added to cultures of Jurkat cells ( $10^7$ ) in

2.5 ml OPTI-MEM and cultured at 37°C in 5% CO<sub>2</sub> for 4 hrs before adding 15 ml RPMI-1640, 10% FBS complete medium (40 µM final oligonucleotide concentration) and returning cells to culture. The oligonucleotide delivery procedure was  
5 repeated on days 1 and 2. At 3 days after initiating cultures, the cells were stimulated or not stimulated with soluble Trail (100 ng/ml) and a crosslinking antibody (2 µg/ml) (ALEXIS Biochemicals) for 16 hrs before preparing cell lysates for immunoblot analysis or determining cell  
10 viability by trypan blue dye exclusion assay.

As shown in Figure 3G, sense (S) or antisense (AS) oligonucleotides targeting DAP3 (Figure 3G, top panel) were introduced into Jurkat cells by lipofection. After 1 day, cells were cultured with (+) or without (-) 0.1 µg/ml  
15 soluble TRAIL for 16 hrs. Half of these cells were used for cell viability assays (% dead cells; mean ± S.D.; n = 3) (Figure 3G, middle panel) and half were lysed and used for assessment of DAP3 and DR4 protein levels by immunoblotting (samples normalized for total protein content) (Figure 3G,  
20 lower panel).

Association of DAP3 with DR4 and DR5 was confirmed by co-immunoprecipitation experiments using transiently transfected HEK293T cells (Figure 3A). In contrast, DAP3 did not co-immunoprecipitate with a DR4 mutant lacking the  
25 DD. Endogenous DAP3 protein could also be co-immunoprecipitated with endogenous DR4 after stimulation with TRAIL, indicating a ligand-inducible interaction (Figure 3A).

To explore whether DAP3 directly binds the cytosolic domain of DR4, both proteins were expressed in bacteria, purified, and tested for interactions. As shown in Figure 3B, DAP3-His<sub>6</sub> bound to GST-DR4 (cytosolic domain) 5 but not to GST, GST-Fas or GST-TNFR2. Scatchard analysis indicated that DAP3 binds the cytosolic domain of DR4 with high-affinity ( $K_D \sim 16$  nM), supporting the notion that this interaction is physiologically relevant. The region within DAP3 required for binding DR4 was also mapped by expressing 10 the DAP3(ΔN) and DAP3(ΔC) proteins. DR4 was determined to bind the proximal domain of DAP3 (Figure 3C). Thus, the proximal region of DAP3 (residues 1-230) binds the DD of DR4, whereas the distal region (residues 231-398) binds the DED of FADD.

15 These results suggested that DAP3 potentially could serve as the missing link between the Trail receptors and FADD. To test this hypothesis, yeast 3-hybrid experiments were performed to determine whether DAP3 could mediate interactions between FADD and the cytosolic domains 20 of DR4 and DR5 in a heterologous cellular background. Indeed, whereas FADD fused to a transactivation domain (TA) failed to bind the cytosolic domains of DR4 or DR5 fused to the DNA-binding domain of a transcription factor in the absence of DAP3, co-expression of DAP3 with these proteins 25 induced reporter gene activation (Figure 3D). In contrast, DAP3ΔN and DAP3ΔC did not reconstitute 3-hybrid interactions in these assays. Thus, DAP3 can bridge FADD to the cytosolic domains of DR4 and DR5.

The nucleotide-dependence of DAP3 interactions with TRAIL receptors was examined by addition of GTP or GTP $\gamma$ S (as well as ATP or ATP $\gamma$ S, used as controls) to lysates prior to co-immunoprecipitation (Figure 3E). GTP 5 enhanced while GTP $\gamma$ S inhibited association of DAP3 with FADD and with pro-Casp8. In contrast, binding of DR4 to DAP3 was unaffected by nucleotides. Therefore, GTP-binding is critical for DAP3 interactions with FADD and pro-Casp8 but not with TRAIL receptors.

10 The functional significance of DAP3 for apoptosis induction by DR4 and DR5 was interrogated by either over-expressing dominant-negative mutants of DAP3 in cells (Figure 3F) or by ablating endogenous DAP3 expression using antisense oligonucleotides (Figure 3G). Both approaches 15 resulted in suppression of cell death caused either by over-expression of Trail-receptors or treatment of cells with soluble purified Trail protein. Thus, DAP3 is a critical component of the Trail receptor signal transduction apparatus.

20 **IV. Sequence Analysis of DAP3 and Identification of DED and NB-ARC Domains**

DAP3 was first discovered during a screen for suppressors of interferon- $\gamma$ -induced apoptosis of HeLa cells using a functional cloning strategy in which cDNA are 25 expressed in antisense orientation (Kissil et al., J. Biol. Chem. 270:27932-27936 (1995)). Based on BLAST searches, DAP3 lacks significant homology to other known apoptosis regulators. However, the functional evidence linking DAP3 to caspase activation and its ability to interact with the

DEDs of FADD and pro-Casp8 prompted a more carefully analysis of the sequence of this protein using other methods. For sequence analysis, sequence alignments were performed using MEG-ALIGN (DNASTar, Inc.; Madison WI).  
5 Molecular modeling was performed using MODELLER (Sali and Blundell, J. Mol. Biol. 234:779-815 (1993)) and FFAST (Jaroszewski et al., Protein Science 7:1431-1440 (1998)).

Figure 4 shows sequence analysis of DAP3, revealing similarities to DED and NB-ARC domains. Figure 4A  
10 shows a schematic representation of human DAP3 protein, indicating locations of NB-ARC-like and DED-like domain, as well as the position of the P-loop motif. Amino acid positions are indicated by numbers. Figure 4B shows an alignment of the amino acid sequence of NB-ARC domains of  
15 human Apaf-1 and *C. elegans* CED4 with residues 115-213 of DAP3. Asterisks indicate nucleotide-binding motifs. Figure 4C shows a sequence alignment of DEDs of pro-Casp8, 10, and FADD with residues 268-337 of DAP3. Identical and similar residues are indicated in black and gray blocks,  
20 respectively.

Alignment of the N-terminal domain of DAP3 (residues 115-213) with the caspase-activating proteins Apaf-1 and CED4 reveals a region of amino-acid sequence similarity (29% and 21%, respectively), which includes the  
25 predicted nucleotide-binding motifs (G-K-S/T) of these proteins (Figure 4A and B). In comparison, the NB-ARC of human Apaf-1 and *C. elegans* CED4 are 17% similar. The C-terminal domain of DAP3 (residues 268 to 337) shares amino acid sequence similarity with the DEDs of FADD, pro-Casp8  
30 and 10 (Figure 4C), ranging from 12-25% (mean 19.2%) amino

acid similarity. In comparison, the DEDs of FADD, pro-Casp8 and pro-Casp10 are 18-39% similar (mean 29.5%).

Gene ablation studies in mice indicate that caspase-8 represents the essential apical caspase in TNF-family death receptor signaling (Varfolomeev et al., Immunity 9:267-276 (1998); Juo et al., Curr. Biol. 8:1001-1008 (1998)). The zymogen form of caspase-8 (p45) possesses roughly 1% of the protease activity of the processed fully-active enzyme, and thus bringing pro-Casp8 molecules into close apposition can allow them to trans-processes each other via the "induced-proximity" mechanism (Muzio et al., J. Biol. Chem. 273:2926-2930 (1998)). Caspase-8 activation can be achieved experimentally by over-expressing pro-Casp8, relying on self-association of its N-terminal DED-containing prodomain. or by fusing the unprocessed catalytic domain (p20/p10) to heterologous dimerization domains (Salvesen et al., Proc. Natl. Acad. Sci. USA 96:10964-10967 (1999)). *In vivo*, however, where levels of pro-Casp8 are probably limiting, caspase-8 activation requires assembly of a multiprotein death-induced signaling complex (DISC). DAP3 represents a previously unrecognized component of this complex. The ability of DAP3 to bind GTP raises the possibility that it can function as a GTP-dependent molecular-switch for mediating protein interactions analogous to Ras and G-proteins. Though ATP/dATP-dependent oligomerization of caspase-activating CED4/Apafl-family proteins has been described (Yang et al., Science 281:1355-1357 (1998); Srinivasula et al., Mol. Cell 1:949-957 (1998)) self-association of DAP3 has not been observed, suggesting a different mechanism is involved. Since small-molecule drugs have been developed against the nucleotide-binding pockets

of kinases, similar approaches can be employed to identify pharmacological antagonists of DAP3 for suppression of death receptor signaling in inflammatory, autoimmune, and ischemic diseases, where TNF-family death receptors play a role  
5 (Nagata, *Genes Cells* 1:873-879 (1996); Wang and Lenardo, *Curr. Opin. Immunol.* 9:818-825 (1997)).

#### **V. IRAK Protein Containing Death Domain**

This example describes a novel death domain-containing protein of the IRAK family.

10 IRAK kinases are signal transducers for the Toll/IL-1 receptor family. All members of this family are involved in host defense. The first signaling event for these receptors is the ligand-induced recruitment of cytosolic MyD88 to the receptor complex (Figure 5). MyD88  
15 in turn acts as an adapter for recruiting IRAK family proteins. IRAK is phosphorylated, then leaves the receptor complex and interacts with TRAF6. This interaction triggers a kinase cascade that eventually leads to the activation of members of the rel and AP-1 family of transcription factors.

20 A previously known putative protein kinase was originally cloned by immunoscreening of cDNA expression libraries prepared from 4 different renal cell carcinomas. The closest homologues of this protein are members of the Interleukin-1 Receptor-Associated Kinase family, IRAK,  
25 IRAK-2 and IRAK-M, and Drosophila kinase PELLE. Sequence analysis of this protein was performed, and it was

BIOLOGICAL MATERIALS

determined that it is another member of the IRAK family. It is therefore called IRAK-4. All these kinases have a death domain (DD) at their N-terminus and a kinase domain at their C-terminus.

5 On the basis of the published sequence of IRAK-4, different sets of primers were designed and used to amplify first-strand cDNAs from kidney and placenta. The primers used to clone IRAK-4 were: Forward primer (nucleotides 1-27 of IRAK-4), 5'-**GC****GAATT**CATGAACAAACCCATAACACCATAACA-3' (SEQ ID NO:42); Reverse primer (nucleotides 1357-1383 of IRAK-4), 5'-**GC****CTCGAG**TAAAGAAGCTGTCATCTCTGCAGCAG-3' (SEQ ID NO:43). The bold indicates restriction sites used for cloning. Two amplification products were always obtained that differed in size by about 150 bp. Both bands were cloned and sequenced.  
10  
15 The longer form of IRAK-4 (SEQ ID NO:15) was found to correspond to the published sequence (SEQ ID NO:27) (GI 5360131, locus AF155118, accession No. AAD42884; GI 7705841; GI 7705840), except that the sequence differed from the previously known sequence near the 3' end of SEQ ID NO:15 at  
20 nucleotides 1295 (T), 1301 (T), 1310 (T), 1332 (A) and 1353 (A) (Figure 10). The shorter form of IRAK-4 lacks 146 bp at the end of the DD. The short form of IRAK-4 deletes nucleotides 162 to 307 of the IRAK-4 long form. Moreover,  
25 an EST clone (GenBank accession No. AA114228) confirmed the existence of the short form, so therefore different isoforms of IRAK-4 appear to exist.

The death domain of IRAK-4 corresponds to nucleotides 25 to 318 (SEQ ID NO:5) of SEQ ID NO:15. The DD corresponds to amino acids 9 to 106 (SEQ ID NO:6) of SEQ ID  
30 NO:16.

Both the long and the short forms of IRAK-4 cDNA were *in vitro* translated, and the *in vitro* translated proteins obtained were of different size. The deletion in the short form affects the last 2  $\alpha$ -helices of the 5 5  $\alpha$ -helices in which the DD is organized. Therefore, the short form of IRAK-4 is expected to have altered binding or no longer be able to bind the binding partners that bind to the DD in the long form of IRAK-4.

To characterize the expression of IRAK-4, Northern 10 blot on poly (A)<sup>+</sup> RNA from various tissues was performed using the IRAK-4 open reading frame (ORF) as a probe. Briefly, multiple tissue Northern blots were hybridized with a <sup>32</sup>P-labeled cDNA fragment encoding full length IRAK-4. The tissues tested were: peripheral blood leukocytes (PBL), 15 colon, small intestine, ovary, testis, prostate, thymus and spleen. IRAK-4 mRNAs were widely expressed in the adult human tissues examined, with different isoforms ranging from 2.4 to 5.0 kb (Figure 6).

Since IRAKs are signal transducers for the 20 Toll, IL-1 receptor family, analysis of the interactions between IRAK-4 and proteins of the Toll/IL-1 receptor transduction pathway was performed. Flag-tagged Toll was expressed in 293T cells, alone or together with HA-tagged IRAK-4. Briefly, 293T cells were transfected with 4  $\mu$ g of 25 Myc-tagged Traf6 (Figure 7A), Flag-tagged hToll (Figure 7B) or His-tagged MyD88 (Figure 7C), alone or together with 4  $\mu$ g of expression plasmid for HA-tagged IRAK-4. After 40 h, cell lysates were prepared and immunoprecipitated (IP) with the corresponding antibodies. Coprecipitating IRAK-4 was 30 detected using anti-HA antibody. Immunoblotting analysis of

RECEIVED  
JULY 22 1997  
BOSTON LIBRARIES

the anti-Flag immunoprecipitates showed that IRAK-4 interacts *in vivo* with hToll (Figure 7B). Similarly, immunoblotting analysis of the anti-Myc and anti-His immunoprecipitates similarly showed that IRAK-4 also 5 interacts *in vivo* with the respectively tagged proteins, the adapter protein MyD88 (Figure 7C) and Traf6 (Figure 7A).

The function of IRAK-4 in regulation of NF $\kappa$ B activity was also characterized. Briefly, 293 cells were transfected with 0.1  $\mu$ g of pNF $\kappa$ B-luc reporter plasmid, 0.1 10  $\mu$ g of pCMV $\beta$ gal and different amounts of expression plasmid for IRAK4 (Figure 8A), IRAK4 and different amount of expression plasmid for dominant negative-Traf6 (Figure 8B), MyD88 and different amount of expression plasmid for the Death Domain of IRAK4 (Figure 8C). Thirty hours after 15 transfection, luciferase activities were determined and normalized on the basis of  $\beta$ -galactosidase activity (Figure 8). The Y axis represents the fold of luciferase activity induction relative to cells transfected with empty vector.

The results of the effect of IRAK-4 on NF $\kappa$ B activation are shown in Figure 8. The results show that 20 overexpression of IRAK-4 can stimulate NF $\kappa$ B activation in a dose-dependent manner (Figure 8A). Overexpression of a dominant negative form of Traf6 inhibits this IRAK4-mediated NF $\kappa$ B activation (Figure 8B). Moreover, expression of IRAK-4 25 death domain alone has a dominant negative effect on MyD88-induced NF $\kappa$ B activation.

## VI. Chlamydia Death Domain Proteins

This example describes novel death domain proteins of *Chlamydia* species.

5   Cloning of Chlamydia Death Domain Proteins:

A computational biology approach was used to search for death domain proteins in *Chlamydia* species. For this approach, a representative set of death domains was used as queries and a cascade of TBLASTN and PSI-BLAST 10 searches were performed on nucleotide databases at NCBI (htgs, gss, dbest) and the NR protein database. Using sequence comparison, a hypothetical protein of unknown function from *C. trachomatis*, designated CT610, was found to contain a putative death domain. The new candidate death 15 domain was confirmed by running a FFAS sequence comparison against a database of proteins of known structure (PDB) enriched for apoptotic domains. The *C. trachomatis* hypothetical protein CT610 (GI: 3329055) had 26% identity and a FFAS Z-score = 9.3 (similarity measure) with human 20 DR5, 29% identity with human DR4 and 25% identity with human Fas when using GAP alignment methods. This degree of sequence identity is comparable to the homology shared among the TNF-Receptor family members. Secondary structure prediction methods showed that the death domain of CT610 can 25 be comprised of six  $\alpha$ -helices, similar to mammalian death domains. Portions of the CT610 protein outside the death domain showed no similarity to known domains in public databases. In addition, homologues of this death domain containing protein were found in three other *Chlamydia* 30 species (*Chlamydia muridarum*, *C. pneumoniae*, and *C. psittaci*) (Figure 11).

The CT610 gene was found within the complementary strand of GenBank accession No. AE001331 (gi|3329046|gb|AE001331.1|; *Chlamydia trachomatis* section 58 of 87 of the complete genome) in close proximity to the 5 *Chlamydia rpoD* gene encoding the major sigma factor ( $\sigma^{66}$ ) which produces a transcription factor implicated in late-gene expression. The nucleotide sequence of CT610 is referenced as SEQ ID NO:23, and the encoded amino acid sequence is referenced as SEQ ID NO:24. Table 2 summarizes 10 characteristics of the CT610 polypeptide.

Table 2. Characteristics of CT610 Polypeptide

	Molecular Weight 26733.28 Daltons
	231 Amino Acids
15	23 Strongly Basic(+) Amino Acids (K,R)
	40 Strongly Acidic(-) Amino Acids (D,E)
	81 Hydrophobic Amino Acids (A,I,L,F,W,V)
	55 Polar Amino Acids (N,C,Q,S,T,Y)
20	4.802 Isoelectric Point
	-15.702 Charge at PH 7.0
	Total number of bases translated is 696
	% A = 30.17 (210)
	% G = 23.56 (164)
	% T = 31.47 (219)
25	% C = 14.80 (103)
	% Ambiguous = 0.00 (0)
	% A+T = 61.64 (429)
	% C+G = 38.36 (267)
30	Davis, Botstein, Roth Melting Temp C. 79.91
	Wallace Temp C 2132.00

Using flanking primers, CT-610 was cloned from genomic DNA of *Chlamydia trachomatis*, LGV-II, strain 434 (ABI/Maryland). The primers used were 5' primer ATGATGGAGGTGTTATG (SEQ ID NO:44) and 3' primer 5 ATAAGATTGATGACAACTAC (SEQ ID NO:45). The cloned product was designated CTDD. The nucleotide sequence of CTDD is referenced as SEQ ID NO:19, and the amino acid sequence is referenced as SEQ ID NO:20. Table 3 summarizes characteristics of the CTDD polypeptide.

10

Table 3. Characteristics of CTDD Polypeptide

15

20

25

Molecular Weight	26832.42 Daltons
231 Amino Acids	
24 Strongly Basic(+) Amino Acids (K,R)	
40 Strongly Acidic(-) Amino Acids (D,E)	
81 Hydrophobic Amino Acids (A,I,L,F,W,V)	
55 Polar Amino Acids (N,C,Q,S,T,Y)	
4.872 Isoelectric Point	
-14.702 Charge at PH 7.0	
Total number of bases translated is 696	
% A = 29.89	(208)
% G = 23.71	(165)
% T = 31.47	(219)
% C = 14.94	(104)
% Ambiguous = 0.00	(0)
% A+T = 61.35	(427)
% C+G = 38.65	(269)
Davis, Botstein, Roth Melting Temp C.	80.03
Wallace Temp C	2138:00

RECORDED BY COMPUTER

The cloned CTDD sequence was found to differ from the published CT-610 sequence at 3 bases. The differing bases are shown in Table 4. Two are silent mutations, but the G->C exchange at bp 664 encodes a different amino acid 5 at position 222, changing G->R.

Table 4. Nucleotide Changes from CT-610 to CTDD

bp 75	A->G silent mutation
bp 615	A->G silent mutation
bp 664	G->C leads to amino acid exchange G->R

10 The death domain of CTDD was identified as nucleotides 268 to 462 (SEQ ID NO:9) of SEQ ID NO:19 and amino acids 90 to 154 (SEQ ID NO:10; DLW...KIR) of SEQ ID NO:20.

15 The cloned sequence was confirmed from several independent clones and then sub-cloned into expression vectors. The ORF encoding CTDD was subcloned into the EcoRI-XhoI sites of pGEX4T1(Pharmacia), pcDNA3-HA (Invitrogen), pcDNA3-myc, and the EcoRI-SalI sites of pEGFP N3. A cDNA encoding myc-CTDD fusion was subcloned into the 20 Hind III and SalI sites of pEGFP-N1 and pERFP-N1 (Clontech). Confocal microscopy analysis of cells transfected with a plasmid encoding a RFP-CTDD fusion protein demonstrated a cytosolic location.

Table 5 shows a comparison of various amino acid 25 positions in CTDD to TNFR1, DR4, DR5 and Fas, with corresponding loss of function (LoF) mutations indicated. The "\*" indicates a Fas lpr mutation, which is a single

amino acid exchange in murine Fas leading to loss of function of the receptor. Mice bearing this mutation exhibit autoimmune disease. This important amino acid (Val in Fas at position 242) is conserved in *Chlamydia* CTDD.

5

Table 5. Comparison of Amino Acids in CTDD and TNFR1, DR4, DR5 and Fas.

<b>aa-Position</b>	<b>TNF R1</b>	<b>DR-4</b>	<b>DR-5</b>	<b>Fas</b>	<b>CT</b>	<b>LoF</b>
10 232	F	L	L	F	F	
	R	R	R	R	F	A
	L	L	L	V*	V	N
	D	K	D	K	P	A
	D	D	K	D	E	A

15 Interaction of CTDD with Other DD-Family Proteins:

CTDD was tested for interactions *in vitro* with a variety of human DD-family proteins, including TNF-family death receptors (TNFR1, DR4, DR5, Fas [CD95]), adapter proteins (FADD, RIP, RAIDD), and c-FLIP. For these experiments CTDD was produced as a GST-fusion protein and incubated with various *in vitro* translated,  $^{35}\text{S}$ -labeled DD-family proteins. Briefly, the plasmid pGEX4T-CTDD was introduced into *E.coli* strain XL1-Blue. Glutathione S-transferase (GST) fusion proteins were obtained by induction with 0.1 mM Isopropyl  $\beta$ -thiogalactoside at 25°C for 8 hours and then purified by using glutathione-Sepharose. Plasmids containing various DD-containing proteins were *in vitro* transcribed and translated in the presence of [ $^{35}\text{S}$ ]L-methionine using the TNT kit from Promega. GST-CTDD and control GST-CD40

RECEIVED  
MAY 1997  
BOSTON  
LIBRARIES

(cytosolic domain) fusion proteins (1 µg) were immobilized on glutathione-Sepharose (Amersham, Pharmacia) and then mixed with 1 µl *in vitro* translated <sup>35</sup>S-labeled target proteins for 1 hr at 4°C. Beads were then washed three 5 times in 1 ml of 140 mM KCl, 20 mM Hepes pH 7.5, 5 mM MgCl<sub>2</sub>, 2 mM EGTA, 0.5% NP40 and bound proteins were analyzed by SDS/PAGE and autoradiography. The results of the protein-protein interaction assay are shown in Table 6.

10 Table 6. *In vitro* Interactions with CTDD and Various  
15 Polypeptides

	In vitro translated protein	GST-CD40	GST-CTDD
	Luciferase	-	-
15	FADD	-	-
	RAIDD	-	-
	RIP	-	-
	c-Flip	-	-
	CTDD (self association)	-	+/-
	Fas without DD	-	-
20	Dr-4	-	+++
	Dr-5	-	+++
	Fas	-	+++
	TNF-RI	-	+

- 25 -: no interaction  
 (+/-): less than 5% of input retrieved  
 +: less than 10% of input retrieved  
 ++: approx. 10% input retrieved  
 +++: more than 10% input retrieved

Based on the *in vitro* binding assay results shown 30 in Table 6, GST-CTDD, but not GST-CD40 or a variety of other control proteins, bound TNF-family death receptors, Fas, DR4, DR5, and to some extent TNFR1. However, CTDD did not significantly interact *in vitro* with FADD, RAIDD, RIP, c-FLIP, itself (CTDD), or a Fas-mutant lacking its DD.

Further, co-immunoprecipitation experiments also demonstrated that CTDD is capable of specifically interacting with TNF-family death receptors such as DR5 in mammalian cells. Briefly, 293 cells ( $5 \times 10^6$ ) were cultured 5 in the presence of 50  $\mu\text{M}$  benzoyl-Val-Ala-Asp-fluoromethylketone (zVAD-fmk) (Enzyme Systems Products), in order to preserve cell viability, and co-transfected with 1  $\mu\text{g}$  pcDNA3-DR5, pERFP-myc-CTDD, pcDNA3-myc-XIAP, pcDNA3-Flag-Casp9, using a lipofection 10 reagent (Bioporter, Gene Therapy Systems). At 24 hrs post-infection, cells were collected, washed with ice-cold PBS, and resuspended in lysis buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.2% Nonidet P40, 10% glycerol and complete protease inhibitor cocktail (Roche)) for 15 min. on 15 ice. The lysate was cleared twice by centrifugation at 16,000g for 10 min. at 4°C. The soluble fraction was precleared with 20  $\mu\text{L}$  protein-G-Sepharose 4B (Zymed) overnight at 4°C and immunoprecipitated with 10  $\mu\text{L}$  anti-myc (Santa Cruz Biotechnology) conjugated Sepharose beads for 4 20 hrs at 4°C. Beads recovered by centrifugation were then washed four times with 1 ml lysis buffer and boiled in Laemmli loading solution before performing SDS-PAGE and immunoblotting using anti-DR-4/DR5 (Alexis), monoclonal mouse anti-Flag (Sigma), or monoclonal mouse anti-myc 25 (Zymed) followed by horse radish peroxidase-conjugated goat anti-mouse-IgG antibodies (Bio-Rad). Detection was accomplished using Enhanced Chemiluminescence (ECL) (Amersham).

The co-immunoprecipitation experiment confirmed an 30 interaction between CTDD and DR-5 (see Figure 12). In the same experiment XIAP did not interact with DR-5 and CTDD did

not interact with caspase 9. However, caspase 9 did interact with XIAP as expected, and serves as a positive control for the experiment.

5    Apoptosis Induction and Caspase Activation by CTDD:

Transfection experiments were performed to test the effects of CTDD on apoptosis in mammalian cells (see Figure 13). Briefly, HeLa (panel A) and Hep3B (panel B) were maintained in DMEM (Irvine Scientific) and supplemented 10 with 10% FBS, 1 mM L-glutamine, and antibiotics. Cells ( $10^6$ ) were transfected with 1  $\mu$ g of pEGFP control, pEGFP-CTDD, pEGFP-DR5-death domain, or CrmA, alone or in combination, normalizing total DNA content. In some cases 100  $\mu$ M zVAD-fmk was added to cultures. Both floating and adherent cells 15 were recovered 1 day later, pooled, and staining with 0.1  $\mu$ g/ml 4'-6-diamidino-2-phenylindole (DAPI). The percentage of GFP-positive cells with apoptotic morphology was determined by UV-microscopic analysis of DAPI-stained cells (mean  $\pm$  SD; n=3) at 1 day after transfection.

20           When transiently transfected into HeLa cells, plasmids producing CTDD induced apoptosis to an extent comparable to a prototypical apoptotic stimuli such as DR-5 and this induction of apoptosis was blocked by addition of zVAD-fmk, an irreversible broad-spectrum caspase inhibitor, 25 to the cultures (Figure 13). In addition, co-expression of the cowpox protein CrmA, a selective inhibitor of caspases-1 and -8, also resulted in blockage of CTDD-induced apoptosis. Immunoblotting experiments confirmed that zVAD-fmk and CrmA did not interfere with CTDD protein production (data not 30 shown). The morphology of the dying cells was typical of

apoptosis, with markedly condensed chromatin, fragmentation of the nucleus, membrane blebbing, cell rounding and shrinkage (data not shown). Thus, CTDD induces apoptosis through a caspase-dependent mechanism.

5

CTDD induced activation of caspases as determined by enzyme assays measuring activity of proteases capable of cleaving a fluorogenic substrate, Ac-DEVD-AFC (see Figure 14). Briefly, HeLa 229 (panel A) and Hep3B (panel B) cells 10 were transfected with 1 µg of pEGFP control, pEGFP-CTDD, pERFP-CTDD, Bax, Fas, or CrmA. Cells were lysed in caspase lysis buffer (10 mM Hepes pH 7.4, 25 mM NaCl, 0.25% Triton X-100, 1 mM EDTA) after 18 hours of transfection. Caspase activity was assayed by release of 15 7-amino-4-trifluoromethyl-coumarin (AFC) from Ac-DEVD-AFC (Calbiochem-Novabiochem) using a spectrofluorimeter. Data are expressed as Relative Fluorescence Units (RFU) per µg total protein (mean ± SD; n=3) after a 30 minute reaction.

When transiently transfected into HeLa cells, 20 plasmids producing CTDD increased caspase activity to an extent comparable to prototypical apoptotic stimuli such as Bax and Fas (Figure 14). In addition, this activation of caspases was reversed in Hep3B cells that were co-transfected with CrmA.

25 Time Course of CTDD Gene Expression and Correlation with Apoptosis:

*Chlamydiae* are obligate intracellular bacteria. These pathogens engage in a unique relationship with their infected host. Upon entering host cells, the parasite 30 undergoes a developmental cycle from the infectious form,

called an elementary body (EB), to a non-infectious, vegetative growth form, called a reticulate body (RB), and then eventually back to the replication-incompetent infectious form. After the transition back to the 5 infectious form, the host cell dies and releases its infectious load. Cytotoxicity due to *Chlamydia* infection is well-recognized (Campbell et al., J. Gen. Micro. 135: 1153-65 (1989)), but the mechanism by which host cells die remains poorly understood. Apoptosis induction at the end 10 of the infectious cycle has been demonstrated, implicating cell death in the mechanism of release of infectious particles (Gibellini et al., Zentralblatt fur Bakteriologie 288:35-43 (1998)).

To determine whether and when CTDD is expressed, 15 RT-PCR analysis was performed. For these experiments HeLa cervical epithelial cell cultures were inoculated with EBs from *C. trachomatis* L2/434/Bu (ATCC) at a multiplicity of infection (MOI) of 2 or 5 and analyzed for apoptosis or CTDD gene expression by RT-PCR analysis. Preparation of EBs and 20 determination of infectivity were performed as described in Campbell et al., *supra*, and Ojcius et al., J. Biol. Chem. 273:7052-8 (1998). HeLa 229 cells were grown in 9 cm Petri dishes to 70% confluence, then infected at a MOI of 2 or 5. To ensure even infection of the cells, plates were gently 25 agitated on a rocking platform for 2 hours at 37°C. To remove unabsorbed EBs, plates were washed three times with PBS, then supplied with fresh medium and incubated at 37°C in a 5% CO<sub>2</sub> humified atmosphere. The percentage of apoptotic cells was determined at various times post- 30 infection by DAPI staining as described above. In addition, at various times post-infection supernatants and adherent

cells were harvested, washed once with PBS, snap-frozen in liquid nitrogen, and stored at -80°C.

RNA from infected HeLa cells was extracted using a modified chloroform/phenol procedure (TRIZOL; Life Technologies). RNA (3 µg) from each sample was treated with DNase I (Roche) and cDNA was generated using reverse transcriptase (RTase) (Superscript II; LIFE TECHNOLOGIES) following the manufacturer's protocol. To detect possible contaminating genomic DNA in the RNA preparations, control reactions containing no reverse transcriptase were performed. A 5% (vol:vol) aliquot of the cDNAs and no-RTase control samples were subsequently amplified by PCR using TAQ DNA polymerase (Qiagen) and the following primer sets: CTDD-forward and reverse (see above); groEL forward 5'-GCAGTCATT CGCGTTGGA-3' (SEQ ID NO:59); and reverse 5'-CGCAGAACGGGACATAACTTG-3' (SEQ ID NO:60); and human β-actin forward 5'- TGATATGCCGCGCTCGTCGTC-3' (SEQ ID NO:61); and reverse 5'- GGATGGCATGGGGAGGGCATA-3' (SEQ ID NO:62). After denaturating DNA at 95°C for 5 min, thermocycling was performed for 45 cycles using 95°C/ 30 s, 55°C /30 s, 72°C/30s with a final extension at 72°C for 5 min. Amplified fragments were analysed by agarose gel-electrophoresis, stained with ethidium bromide, and their identity confirmed by DNA sequencing.

As shown in Figure 15, mRNA corresponding to CTDD became detectable at about 36 hr after infection, reaching maximum levels at 48 to 72 hrs. Thus, CTDD is expressed late in the *Chlamydia* infectious cycle. Furthermore, the timing of CTDD expression is in accordance with the onset and progression of apoptosis in infected HeLa cells.

Roles for CTDD in *Chlamydia* pathophysiology:

As an intercellular parasite, it would be advantageous if intracellular bacteria were able to regulate host cell apoptosis for a wide variety of reasons, including: (a) suppressing apoptosis so that intracellular pathogen replication can occur; (b) inducing apoptosis to facilitate pathogen release, pathogen invasion into tissues, or for creating a source of nutrients from cell corpses; and (c) killing inflammatory cells to avoid immune attack.

Previous studies have established that infection of mammalian cells with *Chlamydiae* species can either suppress or induce apoptosis, depending on whether examined early or late in the infectious cycle of these obligate intracellular bacteria (Fan et al, *J. Exp. Med.* 187:487-96 (1998) and Ojcius et al., *J. Immunol.* 161: 4220-6 (1998)). However, discovery of the responsible bacterial genes has been enigmatic. In the experiments described above, it was demonstrated that the *C. trachomatis* genome contains a gene encoding a bacterial DD protein, CTDD, which is capable of binding several DD-containing TNF-family receptors and inducing caspase activation and apoptosis of human cells. This apoptosis-inducing bacterial gene is located in the late-portion of the circular *C. trachomatis* genome, and is expressed late in the infection cycle, at a time when apoptosis is induced by these bacteria *in vitro*. Closely related genes were also found in the late-portions of the genomes other *Chlamydia* species which create clinically significant infections in various species.

One possible role for CTDD in *Chlamydia* pathophysiology is in the induction of apoptosis to facilitate infectivity. In infected epithelial cells, CTDD

is expressed late in the infectious cycle correlating with the onset of cell death seen *in vitro*. Since CTDD binds the cytosolic domains of DD-containing TNF-family death receptors, CTDD could trigger caspase activation and 5 apoptosis by activating these receptors in a ligand-independent fashion. This is consistent with the ability of CrmA to suppress CTDD-induced apoptosis. CrmA is a selective inhibitor of caspase-8 (and caspase-1), which suppresses apoptosis induced by TNF-family death receptors, 10 but not cell death triggered by stimuli that activate other apoptosis pathways. Alternatively, *in vivo* studies of Chlamydia-induced apoptosis in the endocervix of mice have shown that neutralizing antibodies against TNF-RI can reduce cytotoxicity caused by these bacteria. Thus, it is possible 15 that CTDD sensitizes TNF-family death receptors to their ligands, allowing them to signal more efficiently or increasing the amounts of high-affinity receptors on the cell surface.

20 Another possible role for CTDD in *Chlamydia* pathophysiology is in the induction of apoptosis to avoid immune attack. It has been demonstrated that *Pseudomonas aeruginosa* can trigger apoptosis of macrophages through a Fas-dependent mechanism, demonstrating that these 25 extracellular bacteria deliver signals to mammalian cells that engage death receptor pathways. Since macrophages represent one of the preferred host cells of *Chlamydia* (in addition to epithelial cells), a similar strategy can be employed by *Chlamydia* to evade immune attack.

Another possible role for CTDD in the pathophysiology of *Chlamydiae* is in interference of apoptosis. *Chlamydiae* have been implicated in interference with the eucaryotic death machinery, where an 5 apoptosis-resistant state has been associated with the early replicative phase of the infectious cycle. By lack of a DED, it is possible that CTDD interferes with the DISC (death inducing signalling complex) resulting in disruption of the death signaling cascade.

10 Thus *Chlamydiae* can possess mechanisms for both suppression (early) and induction (late) of host cell apoptosis. This disclosure provides the first demonstration that some types of bacteria harbor apoptosis-regulating genes which share significant sequence similarity with 15 endogenous components of the host cell apoptosis machinery.

#### **VII. Human Death Effector Domain Protein**

This example describes the identification of a novel death effector domain from human.

Using bioinformatics tools, a sequence was 20 identified that contains a death effector domain. Briefly, using the sequences of different death effector domains (DED), GenBank and other DNA/protein databases were searched by "Saturated BLAST" for the existence of new DED-containing proteins (Li et al., Bioinformatics 16:1105-1110(2000)). 25 This search identified two human EST clones (AW449244 and AA218681) that contained a DED most homologous to the DED of DEDD (DED containing DNA-binding protein) (Stegh et al., EMBO J. 17:5974-5986 (1998)). The newly identified gene was

designated DED4 and was predicted from nucleotide sequences (chromosomal DNA and EST DNA) GI Nos. 4210498, 1832773, and 6990020. The nucleotide sequence of DED4 is referenced as SEQ ID NO:17, and the amino acid sequence is referenced as  
5 SEQ ID NO:18.

Using the deduced protein sequences of the EST clones AW449244 and AA218681 in tBLASTn searches, other EST sequences containing overlapping identical nucleotide sequences were identified (BE797255, BE242821, AW229739, and  
10 AW227145). Subsequently, these EST sequences were used to search for more overlapping sequences. The correct reading frame was identified by comparing the sequence of DED4 to the sequences of human DEDD and mouse DED4. DED4 was found to have approximately 50% identity in the nucleotide  
15 sequence with DEDD, and approximately 80% identity in the amino acid sequence. DED4 has its DED at approximately the same position as in DEDD, both proteins are predicted to be about the same size. Similar to DEDD, DED4 has a nuclear localization signal. The DED4 gene is located on chromosome  
20 19, whereas DEDD is located on chromosome 1.

The death effector domain of DED-4 was identified as nucleotides 124 to 426 (SEQ ID NO:7) of SEQ ID NO:17 and amino acids 12 to 112 (SEQ ID NO:8) of SEQ ID NO:18. The nuclear localization sequence was identified as nucleotides  
25 157-222 of SEQ ID NO:17 and amino acids 53 to 74 of SEQ ID NO:18.

DED4 cDNA was amplified from the cDNA of the neuronal precursor cell line NT2 and confirmed by sequencing. The primers used to amplify DED4 were: 5' CTC

CGC CGC CGT CTG G 3' (SEQ ID NO:46) and 5' CGC CCA GGA GTC ATC GGA CGC 3' (SEQ ID NO:47). Northern Blot analysis was performed using a radioactive probe containing the death effector domain in its sequence. Northern analysis revealed 5 a 2.2 kb transcript, which is similar in size to DEDD. Expression of DED4 was observed in most of the human tissues tested in a multiple tissue blot. Expression of DED4 in Northern blot analysis was high in brain, heart, skeletal muscle, kidney, lung and peripheral blood leukocytes. 10 Expression was moderate in thymus and placenta. Expression was weak in colon and small intestine.

DED4 constructs are made, for example as tagged fusions using Myc, HA, His, and the like, and tested for interactions, as described above. DED4 is tested for 15 interactions with itself and DEDD, as well as other molecules that function in apoptosis. Possible interaction partners with DED4 include FADD, caspase-8, caspase-10, FLASH, FLIP and DAP3 and other DED-containing proteins.

#### VIII. Nerve Growth Factor Receptor-interacting Death Domain

20 A mouse EST in the Genbank database (accession No. AV149215) that has homology to mouse p75 nerve growth factor receptor. The EST has 295 base pairs. The NIDD protein was predicted from mouse nucleotide sequences (EST database at NCBI, GI 5353348), and rat and bovine homologues (GI 4607778 25 and GI 6960635, respectively) were also found.

Because this EST was not commercially available, the gene was cloned by RACE. The primers used for RACE were: 5'-RACE primer (5'-CCGAGGTGGCCTGCCAGCTCCTG-3'; SEQ ID

NO:48); 3'- RACE primer (5'-ACACCCGGACCTTGCCTGCCAGCTTAC-3'; SEQ ID NO:49). 3'- and 5'- RACE PCR was performed using RNA from mouse brain. A band about 700 bp long was observed after 5'-RACE, and a band about 600 bp long was observed 5 after 3'-RACE PCR. Sequencing confirmed that 5'-RACE product had a start codon (ATG) and that the 3'-RACE product had a stop codon (TGA). Because about 100 bps of these two products were overlapped, RCR was performed using the two RACE products as templates. The primers for this PCR were 10 5'-ATGCTTTATAACGTCAGC-3' (SEQ ID NO:50) and 5'-TCACACCACCGAGGAGCTCTC-3' (SEQ ID NO:51). The sequencing of this PCR product showed that the gene has 687 nucleotides. The gene was designated NGFR-interacting Death Domain (NIDD) based on its binding with NGFR (see below).

15                 The death domain of NIDD was identified as nucleotides 418 to 630 (SEQ ID NO:11) of SEQ ID NO:21 and amino acids 140-210 (SEQ ID NO:12) of SEQ ID NO:22. A putative transmembrane domain was also identified (nucleotides 157 to 222 of SEQ ID NO:21; amino acids 53 to 20 74 of SEQ ID NO:22, IIPVY...LLAYVAF).

NIDD cDNA was cloned into pcDNA3 vector with myc- and HA-tags. After transfection of pcDNA3-myc -tagged NIDD and pcDNA3-HA- tagged NIDD into 293T cell line, cell lysates were immunoprecipitated with myc-beads and analyzed by 25 Western blotting using anti-HA antibody. Co-immunoprecipitation showed that NIDD has self binding activity. Co-immunoprecipitation experiments were also performed with pcDNA3-HA -tagged NIDD and pcDNA3-FLAG-tagged rat NGF (nerve growth factor)-receptor. NIDD was found to 30 bind to rat NGF-receptor and TRAF-3. The expression of NIDD

was analyzed using 32P-labeled full-length NIDD cDNA. NIDD is expressed in several tissues, including heart, lung, liver, kidney and testis.

Although the invention has been described with  
5 reference to the examples above, it should be understood  
that various modifications can be made without departing  
from the spirit of the invention. Accordingly, the  
invention is limited only by the following claims.

**Summary of Selected Nucleotide and Amino Acid Sequences**

10           **Encoding DD, DED, and NB-ARC containing proteins**

Sequence ID No. 1 is a nucleotide sequence of a  
human DAP3 DED.

Sequence ID No. 2 is an amino acid sequence for a  
human DAP3 DED.

15           Sequence ID No. 3 is a nucleotide sequence of a  
human DAP3 NB-ARC domain.

Sequence ID No. 4 is an amino acid sequence for a  
human DAP3 NB-ARC domain.

20           Sequence ID No. 5 is a nucleotide sequence of a  
human IRAK4 DD.

Sequence ID No. 6 is an amino acid sequence for a  
human IRAK4 DD.

Sequence ID No. 7 is a nucleotide sequence of a human DED4 DED.

Sequence ID No. 8 is an amino acid sequence for a human DED4 DED.

5 Sequence ID No. 9 is a nucleotide sequence of a *C. trachomatis* CTDD DD.

Sequence ID No. 10 is an amino acid sequence for a *C. trachomatis* CTDD DD.

10 Sequence ID No. 11 is a nucleotide sequence of a mouse NIDD DD.

Sequence ID No. 12 is an amino acid sequence for a mouse NIDD DD.

Sequence ID No. 13 is a nucleotide sequence of a full length human DAP3 gene.

15 Sequence ID No. 14 is an amino acid sequence for a full length human DAP3 protein.

Sequence ID No. 15 is a nucleotide sequence of a full length human IRAK4 gene.

20 Sequence ID No. 16 is an amino acid sequence for a full length human IRAK4 protein.

Sequence ID No. 17 is a nucleotide sequence of a full length human DED4 gene.

Sequence ID No. 18 is an amino acid sequence for a full length human DED4 protein.

Sequence ID No. 19 is a nucleotide sequence of a full length *C. trachomatis* CTDD gene.

5 Sequence ID No. 20 is an amino acid sequence for a full length *C. trachomatis* CTDD protein.

Sequence ID No. 21 is a nucleotide sequence of a full length mouse NIDD gene.

10 Sequence ID No. 22 is an amino acid sequence for a full length mouse NIDD protein.

Sequence ID No. 23 is a nucleotide sequence of a full length *C. trachomatis* CT-610 gene.

Sequence ID No. 24 is an amino acid sequence for a full length *C. trachomatis* CT-610 protein.

15 Sequence ID No. 25 is a nucleotide sequence of a full length human IRAK4 short gene.

Sequence ID No. 26 is an amino acid sequence for a full length human IRAK4 short protein.

20 Sequence ID No. 27 is a nucleotide sequence of a full length human IRAK4 gene from Genbank sequence.

Sequence ID No. 28 is an amino acid sequence for a full length human IRAK4 protein from Genbank sequence.

Sequence ID No. 52 is a nucleotide sequence of a  
*C. muridarum* CTDD DD.

Sequence ID No. 53 is an amino acid sequence for a  
*C. muridarum* CTDD DD.

5 Sequence ID No. 54 is a nucleotide sequence of a  
full length *C. muridarum* CTDD gene.

Sequence ID No. 55 is an amino acid sequence for a  
full length *C. muridarum* CTDD protein.

10 Sequence ID No. 56 is an amino acid sequence for a  
*C. pneumoniae* CTDD DD.

Sequence ID No. 57 is an amino acid sequence for a  
full length *C. pneumoniae* CTDD protein.

15 Sequence ID No. 58 is an amino acid sequence for a  
*C. psittaci* CTDD DD.